series.release	series.code	series.description	geoAreaCode	X	Y	ISO3CD	geoAreaName	sliceId	Units	Units description	years	value	valueType	time_detail	source	Nature
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	66.02688198	33.83160199	AFG	Afghanistan	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	66.02688198	33.83160199	AFG	Afghanistan	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	66.02688198	33.83160199	AFG	Afghanistan	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	66.02688198	33.83160199	AFG	Afghanistan	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	66.02688198	33.83160199	AFG	Afghanistan	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	66.02688198	33.83160199	AFG	Afghanistan	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	66.02688198	33.83160199	AFG	Afghanistan	1	PERCENT	Percentage	2014	40	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	66.02688198	33.83160199	AFG	Afghanistan	1	PERCENT	Percentage	2015	65	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	66.02688198	33.83160199	AFG	Afghanistan	1	PERCENT	Percentage	2016	65	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	20.06660928	41.13897007	ALB	Albania	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	20.06660928	41.13897007	ALB	Albania	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	20.06660928	41.13897007	ALB	Albania	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	20.06660928	41.13897007	ALB	Albania	1	PERCENT	Percentage	2011	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	20.06660928	41.13897007	ALB	Albania	1	PERCENT	Percentage	2012	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	20.06660928	41.13897007	ALB	Albania	1	PERCENT	Percentage	2013	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	20.06660928	41.13897007	ALB	Albania	1	PERCENT	Percentage	2014	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	20.06660928	41.13897007	ALB	Albania	1	PERCENT	Percentage	2015	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	20.06660928	41.13897007	ALB	Albania	1	PERCENT	Percentage	2016	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	10	21.47585697	-80.40897662	ATA	Antarctica	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	10	21.47585697	-80.40897662	ATA	Antarctica	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	10	21.47585697	-80.40897662	ATA	Antarctica	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	10	21.47585697	-80.40897662	ATA	Antarctica	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	10	21.47585697	-80.40897662	ATA	Antarctica	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	10	21.47585697	-80.40897662	ATA	Antarctica	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	10	21.47585697	-80.40897662	ATA	Antarctica	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	10	21.47585697	-80.40897662	ATA	Antarctica	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	10	21.47585697	-80.40897662	ATA	Antarctica	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	12	2.678164227	28.15940032	DZA	Algeria	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	12	2.678164227	28.15940032	DZA	Algeria	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	12	2.678164227	28.15940032	DZA	Algeria	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	12	2.678164227	28.15940032	DZA	Algeria	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	12	2.678164227	28.15940032	DZA	Algeria	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	12	2.678164227	28.15940032	DZA	Algeria	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	12	2.678164227	28.15940032	DZA	Algeria	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	12	2.678164227	28.15940032	DZA	Algeria	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	12	2.678164227	28.15940032	DZA	Algeria	1	PERCENT	Percentage	2016	61	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	16	-170.7187269	-14.30587306	ASM	American Samoa	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	16	-170.7187269	-14.30587306	ASM	American Samoa	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	16	-170.7187269	-14.30587306	ASM	American Samoa	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	16	-170.7187269	-14.30587306	ASM	American Samoa	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	16	-170.7187269	-14.30587306	ASM	American Samoa	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	16	-170.7187269	-14.30587306	ASM	American Samoa	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	16	-170.7187269	-14.30587306	ASM	American Samoa	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	16	-170.7187269	-14.30587306	ASM	American Samoa	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	16	-170.7187269	-14.30587306	ASM	American Samoa	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	1.576257417	42.54548611	AND	Andorra	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	1.576257417	42.54548611	AND	Andorra	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	1.576257417	42.54548611	AND	Andorra	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	1.576257417	42.54548611	AND	Andorra	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	1.576257417	42.54548611	AND	Andorra	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	1.576257417	42.54548611	AND	Andorra	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	1.576257417	42.54548611	AND	Andorra	1	PERCENT	Percentage	2014	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	1.576257417	42.54548611	AND	Andorra	1	PERCENT	Percentage	2015	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	1.576257417	42.54548611	AND	Andorra	1	PERCENT	Percentage	2016	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	17.57817062	-12.33724746	AGO	Angola	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	17.57817062	-12.33724746	AGO	Angola	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	17.57817062	-12.33724746	AGO	Angola	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	17.57817062	-12.33724746	AGO	Angola	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	17.57817062	-12.33724746	AGO	Angola	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	17.57817062	-12.33724746	AGO	Angola	1	PERCENT	Percentage	2013	9	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	17.57817062	-12.33724746	AGO	Angola	1	PERCENT	Percentage	2014	45	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	17.57817062	-12.33724746	AGO	Angola	1	PERCENT	Percentage	2015	58	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	17.57817062	-12.33724746	AGO	Angola	1	PERCENT	Percentage	2016	58	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	28	-61.7999755	17.07761471	ATG	Antigua and Barbuda	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	28	-61.7999755	17.07761471	ATG	Antigua and Barbuda	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	28	-61.7999755	17.07761471	ATG	Antigua and Barbuda	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	28	-61.7999755	17.07761471	ATG	Antigua and Barbuda	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	28	-61.7999755	17.07761471	ATG	Antigua and Barbuda	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	28	-61.7999755	17.07761471	ATG	Antigua and Barbuda	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	28	-61.7999755	17.07761471	ATG	Antigua and Barbuda	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	28	-61.7999755	17.07761471	ATG	Antigua and Barbuda	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	28	-61.7999755	17.07761471	ATG	Antigua and Barbuda	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	50.01064725	40.39229544	AZE	Azerbaijan	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	50.01064725	40.39229544	AZE	Azerbaijan	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	50.01064725	40.39229544	AZE	Azerbaijan	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	50.01064725	40.39229544	AZE	Azerbaijan	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	50.01064725	40.39229544	AZE	Azerbaijan	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	50.01064725	40.39229544	AZE	Azerbaijan	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	50.01064725	40.39229544	AZE	Azerbaijan	1	PERCENT	Percentage	2014	64	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	50.01064725	40.39229544	AZE	Azerbaijan	1	PERCENT	Percentage	2015	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	50.01064725	40.39229544	AZE	Azerbaijan	1	PERCENT	Percentage	2016	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	-65.14563274	-35.19446255	ARG	Argentina	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	-65.14563274	-35.19446255	ARG	Argentina	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	-65.14563274	-35.19446255	ARG	Argentina	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	-65.14563274	-35.19446255	ARG	Argentina	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	-65.14563274	-35.19446255	ARG	Argentina	1	PERCENT	Percentage	2012	41	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	-65.14563274	-35.19446255	ARG	Argentina	1	PERCENT	Percentage	2013	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	-65.14563274	-35.19446255	ARG	Argentina	1	PERCENT	Percentage	2014	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	-65.14563274	-35.19446255	ARG	Argentina	1	PERCENT	Percentage	2015	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	-65.14563274	-35.19446255	ARG	Argentina	1	PERCENT	Percentage	2016	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	134.3499412	-25.57717202	AUS	Australia	1	PERCENT	Percentage	2008	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	134.3499412	-25.57717202	AUS	Australia	1	PERCENT	Percentage	2009	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	134.3499412	-25.57717202	AUS	Australia	1	PERCENT	Percentage	2010	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	134.3499412	-25.57717202	AUS	Australia	1	PERCENT	Percentage	2011	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	134.3499412	-25.57717202	AUS	Australia	1	PERCENT	Percentage	2012	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	134.3499412	-25.57717202	AUS	Australia	1	PERCENT	Percentage	2013	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	134.3499412	-25.57717202	AUS	Australia	1	PERCENT	Percentage	2014	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	134.3499412	-25.57717202	AUS	Australia	1	PERCENT	Percentage	2015	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	134.3499412	-25.57717202	AUS	Australia	1	PERCENT	Percentage	2016	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	40	14.14172472	47.58704857	AUT	Austria	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	40	14.14172472	47.58704857	AUT	Austria	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	40	14.14172472	47.58704857	AUT	Austria	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	40	14.14172472	47.58704857	AUT	Austria	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	40	14.14172472	47.58704857	AUT	Austria	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	40	14.14172472	47.58704857	AUT	Austria	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	40	14.14172472	47.58704857	AUT	Austria	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	40	14.14172472	47.58704857	AUT	Austria	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	40	14.14172472	47.58704857	AUT	Austria	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	-78.05111663	24.69546597	BHS	Bahamas	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	-78.05111663	24.69546597	BHS	Bahamas	1	PERCENT	Percentage	2009	3	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	-78.05111663	24.69546597	BHS	Bahamas	1	PERCENT	Percentage	2010	1	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	-78.05111663	24.69546597	BHS	Bahamas	1	PERCENT	Percentage	2011	1	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	-78.05111663	24.69546597	BHS	Bahamas	1	PERCENT	Percentage	2012	37	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	-78.05111663	24.69546597	BHS	Bahamas	1	PERCENT	Percentage	2013	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	-78.05111663	24.69546597	BHS	Bahamas	1	PERCENT	Percentage	2014	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	-78.05111663	24.69546597	BHS	Bahamas	1	PERCENT	Percentage	2015	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	-78.05111663	24.69546597	BHS	Bahamas	1	PERCENT	Percentage	2016	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	50.5490754	26.04407747	BHR	Bahrain	1	PERCENT	Percentage	2008	14	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	50.5490754	26.04407747	BHR	Bahrain	1	PERCENT	Percentage	2009	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	50.5490754	26.04407747	BHR	Bahrain	1	PERCENT	Percentage	2010	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	50.5490754	26.04407747	BHR	Bahrain	1	PERCENT	Percentage	2011	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	50.5490754	26.04407747	BHR	Bahrain	1	PERCENT	Percentage	2012	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	50.5490754	26.04407747	BHR	Bahrain	1	PERCENT	Percentage	2013	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	50.5490754	26.04407747	BHR	Bahrain	1	PERCENT	Percentage	2014	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	50.5490754	26.04407747	BHR	Bahrain	1	PERCENT	Percentage	2015	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	50.5490754	26.04407747	BHR	Bahrain	1	PERCENT	Percentage	2016	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	89.17660788	22.86961622	BGD	Bangladesh	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	89.17660788	22.86961622	BGD	Bangladesh	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	89.17660788	22.86961622	BGD	Bangladesh	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	89.17660788	22.86961622	BGD	Bangladesh	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	89.17660788	22.86961622	BGD	Bangladesh	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	89.17660788	22.86961622	BGD	Bangladesh	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	89.17660788	22.86961622	BGD	Bangladesh	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	89.17660788	22.86961622	BGD	Bangladesh	1	PERCENT	Percentage	2015	48	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	89.17660788	22.86961622	BGD	Bangladesh	1	PERCENT	Percentage	2016	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	44.93839317	40.29499741	ARM	Armenia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	44.93839317	40.29499741	ARM	Armenia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	44.93839317	40.29499741	ARM	Armenia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	44.93839317	40.29499741	ARM	Armenia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	44.93839317	40.29499741	ARM	Armenia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	44.93839317	40.29499741	ARM	Armenia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	44.93839317	40.29499741	ARM	Armenia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	44.93839317	40.29499741	ARM	Armenia	1	PERCENT	Percentage	2015	44	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	44.93839317	40.29499741	ARM	Armenia	1	PERCENT	Percentage	2016	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	-59.5346489	13.13648273	BRB	Barbados	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	-59.5346489	13.13648273	BRB	Barbados	1	PERCENT	Percentage	2009	75	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	-59.5346489	13.13648273	BRB	Barbados	1	PERCENT	Percentage	2010	78	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	-59.5346489	13.13648273	BRB	Barbados	1	PERCENT	Percentage	2011	81	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	-59.5346489	13.13648273	BRB	Barbados	1	PERCENT	Percentage	2012	84	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	-59.5346489	13.13648273	BRB	Barbados	1	PERCENT	Percentage	2013	87	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	-59.5346489	13.13648273	BRB	Barbados	1	PERCENT	Percentage	2014	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	-59.5346489	13.13648273	BRB	Barbados	1	PERCENT	Percentage	2015	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	-59.5346489	13.13648273	BRB	Barbados	1	PERCENT	Percentage	2016	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	4.660976456	50.64104975	BEL	Belgium	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	4.660976456	50.64104975	BEL	Belgium	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	4.660976456	50.64104975	BEL	Belgium	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	4.660976456	50.64104975	BEL	Belgium	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	4.660976456	50.64104975	BEL	Belgium	1	PERCENT	Percentage	2012	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	4.660976456	50.64104975	BEL	Belgium	1	PERCENT	Percentage	2013	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	4.660976456	50.64104975	BEL	Belgium	1	PERCENT	Percentage	2014	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	4.660976456	50.64104975	BEL	Belgium	1	PERCENT	Percentage	2015	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	4.660976456	50.64104975	BEL	Belgium	1	PERCENT	Percentage	2016	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	60	-64.78155012	32.27881922	BMU	Bermuda	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	60	-64.78155012	32.27881922	BMU	Bermuda	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	60	-64.78155012	32.27881922	BMU	Bermuda	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	60	-64.78155012	32.27881922	BMU	Bermuda	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	60	-64.78155012	32.27881922	BMU	Bermuda	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	60	-64.78155012	32.27881922	BMU	Bermuda	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	60	-64.78155012	32.27881922	BMU	Bermuda	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	60	-64.78155012	32.27881922	BMU	Bermuda	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	60	-64.78155012	32.27881922	BMU	Bermuda	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	64	90.45098484	27.39598568	BTN	Bhutan	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	64	90.45098484	27.39598568	BTN	Bhutan	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	64	90.45098484	27.39598568	BTN	Bhutan	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	64	90.45098484	27.39598568	BTN	Bhutan	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	64	90.45098484	27.39598568	BTN	Bhutan	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	64	90.45098484	27.39598568	BTN	Bhutan	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	64	90.45098484	27.39598568	BTN	Bhutan	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	64	90.45098484	27.39598568	BTN	Bhutan	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	64	90.45098484	27.39598568	BTN	Bhutan	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	-64.66224284	-16.71273412	BOL	Bolivia (Plurinational State of)	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	-64.66224284	-16.71273412	BOL	Bolivia (Plurinational State of)	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	-64.66224284	-16.71273412	BOL	Bolivia (Plurinational State of)	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	-64.66224284	-16.71273412	BOL	Bolivia (Plurinational State of)	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	-64.66224284	-16.71273412	BOL	Bolivia (Plurinational State of)	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	-64.66224284	-16.71273412	BOL	Bolivia (Plurinational State of)	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	-64.66224284	-16.71273412	BOL	Bolivia (Plurinational State of)	1	PERCENT	Percentage	2014	56	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	-64.66224284	-16.71273412	BOL	Bolivia (Plurinational State of)	1	PERCENT	Percentage	2015	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	-64.66224284	-16.71273412	BOL	Bolivia (Plurinational State of)	1	PERCENT	Percentage	2016	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	70	17.78584332	44.16845548	BIH	Bosnia and Herzegovina	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	70	17.78584332	44.16845548	BIH	Bosnia and Herzegovina	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	70	17.78584332	44.16845548	BIH	Bosnia and Herzegovina	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	70	17.78584332	44.16845548	BIH	Bosnia and Herzegovina	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	70	17.78584332	44.16845548	BIH	Bosnia and Herzegovina	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	70	17.78584332	44.16845548	BIH	Bosnia and Herzegovina	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	70	17.78584332	44.16845548	BIH	Bosnia and Herzegovina	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	70	17.78584332	44.16845548	BIH	Bosnia and Herzegovina	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	70	17.78584332	44.16845548	BIH	Bosnia and Herzegovina	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	23.81380223	-22.18810073	BWA	Botswana	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	23.81380223	-22.18810073	BWA	Botswana	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	23.81380223	-22.18810073	BWA	Botswana	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	23.81380223	-22.18810073	BWA	Botswana	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	23.81380223	-22.18810073	BWA	Botswana	1	PERCENT	Percentage	2012	52	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	23.81380223	-22.18810073	BWA	Botswana	1	PERCENT	Percentage	2013	72	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	23.81380223	-22.18810073	BWA	Botswana	1	PERCENT	Percentage	2014	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	23.81380223	-22.18810073	BWA	Botswana	1	PERCENT	Percentage	2015	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	23.81380223	-22.18810073	BWA	Botswana	1	PERCENT	Percentage	2016	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	74	3.410732868	-54.43295905	BVT	Bouvet Island	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	74	3.410732868	-54.43295905	BVT	Bouvet Island	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	74	3.410732868	-54.43295905	BVT	Bouvet Island	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	74	3.410732868	-54.43295905	BVT	Bouvet Island	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	74	3.410732868	-54.43295905	BVT	Bouvet Island	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	74	3.410732868	-54.43295905	BVT	Bouvet Island	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	74	3.410732868	-54.43295905	BVT	Bouvet Island	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	74	3.410732868	-54.43295905	BVT	Bouvet Island	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	74	3.410732868	-54.43295905	BVT	Bouvet Island	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	-53.08432878	-10.77668561	BRA	Brazil	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	-53.08432878	-10.77668561	BRA	Brazil	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	-53.08432878	-10.77668561	BRA	Brazil	1	PERCENT	Percentage	2010	24	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	-53.08432878	-10.77668561	BRA	Brazil	1	PERCENT	Percentage	2011	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	-53.08432878	-10.77668561	BRA	Brazil	1	PERCENT	Percentage	2012	88	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	-53.08432878	-10.77668561	BRA	Brazil	1	PERCENT	Percentage	2013	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	-53.08432878	-10.77668561	BRA	Brazil	1	PERCENT	Percentage	2014	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	-53.08432878	-10.77668561	BRA	Brazil	1	PERCENT	Percentage	2015	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	-53.08432878	-10.77668561	BRA	Brazil	1	PERCENT	Percentage	2016	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	84	-88.70199554	17.19965901	BLZ	Belize	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	84	-88.70199554	17.19965901	BLZ	Belize	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	84	-88.70199554	17.19965901	BLZ	Belize	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	84	-88.70199554	17.19965901	BLZ	Belize	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	84	-88.70199554	17.19965901	BLZ	Belize	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	84	-88.70199554	17.19965901	BLZ	Belize	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	84	-88.70199554	17.19965901	BLZ	Belize	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	84	-88.70199554	17.19965901	BLZ	Belize	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	84	-88.70199554	17.19965901	BLZ	Belize	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	86	72.38715553	-7.299281071	IOT	British Indian Ocean Territory	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	86	72.38715553	-7.299281071	IOT	British Indian Ocean Territory	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	86	72.38715553	-7.299281071	IOT	British Indian Ocean Territory	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	86	72.38715553	-7.299281071	IOT	British Indian Ocean Territory	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	86	72.38715553	-7.299281071	IOT	British Indian Ocean Territory	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	86	72.38715553	-7.299281071	IOT	British Indian Ocean Territory	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	86	72.38715553	-7.299281071	IOT	British Indian Ocean Territory	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	86	72.38715553	-7.299281071	IOT	British Indian Ocean Territory	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	86	72.38715553	-7.299281071	IOT	British Indian Ocean Territory	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	160.1584117	-9.622391719	SLB	Solomon Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	160.1584117	-9.622391719	SLB	Solomon Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	160.1584117	-9.622391719	SLB	Solomon Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	160.1584117	-9.622391719	SLB	Solomon Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	160.1584117	-9.622391719	SLB	Solomon Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	160.1584117	-9.622391719	SLB	Solomon Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	160.1584117	-9.622391719	SLB	Solomon Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	160.1584117	-9.622391719	SLB	Solomon Islands	1	PERCENT	Percentage	2015	42	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	160.1584117	-9.622391719	SLB	Solomon Islands	1	PERCENT	Percentage	2016	87	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	92	-64.63294223	18.42256578	VGB	British Virgin Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	92	-64.63294223	18.42256578	VGB	British Virgin Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	92	-64.63294223	18.42256578	VGB	British Virgin Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	92	-64.63294223	18.42256578	VGB	British Virgin Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	92	-64.63294223	18.42256578	VGB	British Virgin Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	92	-64.63294223	18.42256578	VGB	British Virgin Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	92	-64.63294223	18.42256578	VGB	British Virgin Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	92	-64.63294223	18.42256578	VGB	British Virgin Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	92	-64.63294223	18.42256578	VGB	British Virgin Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	96	114.6288563	4.49736984	BRN	Brunei Darussalam	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	96	114.6288563	4.49736984	BRN	Brunei Darussalam	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	96	114.6288563	4.49736984	BRN	Brunei Darussalam	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	96	114.6288563	4.49736984	BRN	Brunei Darussalam	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	96	114.6288563	4.49736984	BRN	Brunei Darussalam	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	96	114.6288563	4.49736984	BRN	Brunei Darussalam	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	96	114.6288563	4.49736984	BRN	Brunei Darussalam	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	96	114.6288563	4.49736984	BRN	Brunei Darussalam	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	96	114.6288563	4.49736984	BRN	Brunei Darussalam	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	25.23763153	42.75731323	BGR	Bulgaria	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	25.23763153	42.75731323	BGR	Bulgaria	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	25.23763153	42.75731323	BGR	Bulgaria	1	PERCENT	Percentage	2010	69	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	25.23763153	42.75731323	BGR	Bulgaria	1	PERCENT	Percentage	2011	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	25.23763153	42.75731323	BGR	Bulgaria	1	PERCENT	Percentage	2012	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	25.23763153	42.75731323	BGR	Bulgaria	1	PERCENT	Percentage	2013	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	25.23763153	42.75731323	BGR	Bulgaria	1	PERCENT	Percentage	2014	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	25.23763153	42.75731323	BGR	Bulgaria	1	PERCENT	Percentage	2015	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	25.23763153	42.75731323	BGR	Bulgaria	1	PERCENT	Percentage	2016	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	104	96.51752295	21.19332882	MMR	Myanmar	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	104	96.51752295	21.19332882	MMR	Myanmar	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	104	96.51752295	21.19332882	MMR	Myanmar	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	104	96.51752295	21.19332882	MMR	Myanmar	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	104	96.51752295	21.19332882	MMR	Myanmar	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	104	96.51752295	21.19332882	MMR	Myanmar	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	104	96.51752295	21.19332882	MMR	Myanmar	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	104	96.51752295	21.19332882	MMR	Myanmar	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	104	96.51752295	21.19332882	MMR	Myanmar	1	PERCENT	Percentage	2016	14	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	29.89080992	-3.366387428	BDI	Burundi	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	29.89080992	-3.366387428	BDI	Burundi	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	29.89080992	-3.366387428	BDI	Burundi	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	29.89080992	-3.366387428	BDI	Burundi	1	PERCENT	Percentage	2011	14	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	29.89080992	-3.366387428	BDI	Burundi	1	PERCENT	Percentage	2012	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	29.89080992	-3.366387428	BDI	Burundi	1	PERCENT	Percentage	2013	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	29.89080992	-3.366387428	BDI	Burundi	1	PERCENT	Percentage	2014	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	29.89080992	-3.366387428	BDI	Burundi	1	PERCENT	Percentage	2015	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	29.89080992	-3.366387428	BDI	Burundi	1	PERCENT	Percentage	2016	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	112	28.04940161	53.54193075	BLR	Belarus	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	112	28.04940161	53.54193075	BLR	Belarus	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	112	28.04940161	53.54193075	BLR	Belarus	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	112	28.04940161	53.54193075	BLR	Belarus	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	112	28.04940161	53.54193075	BLR	Belarus	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	112	28.04940161	53.54193075	BLR	Belarus	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	112	28.04940161	53.54193075	BLR	Belarus	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	112	28.04940161	53.54193075	BLR	Belarus	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	112	28.04940161	53.54193075	BLR	Belarus	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	104.922836	12.71163737	KHM	Cambodia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	104.922836	12.71163737	KHM	Cambodia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	104.922836	12.71163737	KHM	Cambodia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	104.922836	12.71163737	KHM	Cambodia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	104.922836	12.71163737	KHM	Cambodia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	104.922836	12.71163737	KHM	Cambodia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	104.922836	12.71163737	KHM	Cambodia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	104.922836	12.71163737	KHM	Cambodia	1	PERCENT	Percentage	2015	68	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	104.922836	12.71163737	KHM	Cambodia	1	PERCENT	Percentage	2016	87	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	12.7419827	5.692387031	CMR	Cameroon	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	12.7419827	5.692387031	CMR	Cameroon	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	12.7419827	5.692387031	CMR	Cameroon	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	12.7419827	5.692387031	CMR	Cameroon	1	PERCENT	Percentage	2011	23	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	12.7419827	5.692387031	CMR	Cameroon	1	PERCENT	Percentage	2012	84	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	12.7419827	5.692387031	CMR	Cameroon	1	PERCENT	Percentage	2013	88	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	12.7419827	5.692387031	CMR	Cameroon	1	PERCENT	Percentage	2014	87	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	12.7419827	5.692387031	CMR	Cameroon	1	PERCENT	Percentage	2015	85	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	12.7419827	5.692387031	CMR	Cameroon	1	PERCENT	Percentage	2016	84	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	-101.6575058	57.72360191	CAN	Canada	1	PERCENT	Percentage	2008	42	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	-101.6575058	57.72360191	CAN	Canada	1	PERCENT	Percentage	2009	50	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	-101.6575058	57.72360191	CAN	Canada	1	PERCENT	Percentage	2010	58	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	-101.6575058	57.72360191	CAN	Canada	1	PERCENT	Percentage	2011	66	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	-101.6575058	57.72360191	CAN	Canada	1	PERCENT	Percentage	2012	73	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	-101.6575058	57.72360191	CAN	Canada	1	PERCENT	Percentage	2013	79	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	-101.6575058	57.72360191	CAN	Canada	1	PERCENT	Percentage	2014	79	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	-101.6575058	57.72360191	CAN	Canada	1	PERCENT	Percentage	2015	79	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	-101.6575058	57.72360191	CAN	Canada	1	PERCENT	Percentage	2016	79	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	132	-23.63544151	15.07791834	CPV	Cabo Verde	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	132	-23.63544151	15.07791834	CPV	Cabo Verde	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	132	-23.63544151	15.07791834	CPV	Cabo Verde	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	132	-23.63544151	15.07791834	CPV	Cabo Verde	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	132	-23.63544151	15.07791834	CPV	Cabo Verde	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	132	-23.63544151	15.07791834	CPV	Cabo Verde	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	132	-23.63544151	15.07791834	CPV	Cabo Verde	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	132	-23.63544151	15.07791834	CPV	Cabo Verde	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	132	-23.63544151	15.07791834	CPV	Cabo Verde	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	136	-81.16740559	19.32266656	CYM	Cayman Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	136	-81.16740559	19.32266656	CYM	Cayman Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	136	-81.16740559	19.32266656	CYM	Cayman Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	136	-81.16740559	19.32266656	CYM	Cayman Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	136	-81.16740559	19.32266656	CYM	Cayman Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	136	-81.16740559	19.32266656	CYM	Cayman Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	136	-81.16740559	19.32266656	CYM	Cayman Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	136	-81.16740559	19.32266656	CYM	Cayman Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	136	-81.16740559	19.32266656	CYM	Cayman Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	20.93559492	7.003720791	CAF	Central African Republic	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	20.93559492	7.003720791	CAF	Central African Republic	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	20.93559492	7.003720791	CAF	Central African Republic	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	20.93559492	7.003720791	CAF	Central African Republic	1	PERCENT	Percentage	2011	8	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	20.93559492	7.003720791	CAF	Central African Republic	1	PERCENT	Percentage	2012	47	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	20.93559492	7.003720791	CAF	Central African Republic	1	PERCENT	Percentage	2013	23	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	20.93559492	7.003720791	CAF	Central African Republic	1	PERCENT	Percentage	2014	47	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	20.93559492	7.003720791	CAF	Central African Republic	1	PERCENT	Percentage	2015	47	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	20.93559492	7.003720791	CAF	Central African Republic	1	PERCENT	Percentage	2016	47	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	144	80.70489654	7.614693343	LKA	Sri Lanka	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	144	80.70489654	7.614693343	LKA	Sri Lanka	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	144	80.70489654	7.614693343	LKA	Sri Lanka	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	144	80.70489654	7.614693343	LKA	Sri Lanka	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	144	80.70489654	7.614693343	LKA	Sri Lanka	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	144	80.70489654	7.614693343	LKA	Sri Lanka	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	144	80.70489654	7.614693343	LKA	Sri Lanka	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	144	80.70489654	7.614693343	LKA	Sri Lanka	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	144	80.70489654	7.614693343	LKA	Sri Lanka	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	148	18.66618401	15.36279341	TCD	Chad	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	148	18.66618401	15.36279341	TCD	Chad	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	148	18.66618401	15.36279341	TCD	Chad	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	148	18.66618401	15.36279341	TCD	Chad	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	148	18.66618401	15.36279341	TCD	Chad	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	148	18.66618401	15.36279341	TCD	Chad	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	148	18.66618401	15.36279341	TCD	Chad	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	148	18.66618401	15.36279341	TCD	Chad	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	148	18.66618401	15.36279341	TCD	Chad	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	-71.23029019	-35.2652885	CHL	Chile	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	-71.23029019	-35.2652885	CHL	Chile	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	-71.23029019	-35.2652885	CHL	Chile	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	-71.23029019	-35.2652885	CHL	Chile	1	PERCENT	Percentage	2011	54	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	-71.23029019	-35.2652885	CHL	Chile	1	PERCENT	Percentage	2012	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	-71.23029019	-35.2652885	CHL	Chile	1	PERCENT	Percentage	2013	79	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	-71.23029019	-35.2652885	CHL	Chile	1	PERCENT	Percentage	2014	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	-71.23029019	-35.2652885	CHL	Chile	1	PERCENT	Percentage	2015	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	-71.23029019	-35.2652885	CHL	Chile	1	PERCENT	Percentage	2016	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	156	104.1403375	32.30955217	CHN	China	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	156	104.1403375	32.30955217	CHN	China	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	156	104.1403375	32.30955217	CHN	China	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	156	104.1403375	32.30955217	CHN	China	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	156	104.1403375	32.30955217	CHN	China	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	156	104.1403375	32.30955217	CHN	China	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	156	104.1403375	32.30955217	CHN	China	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	156	104.1403375	32.30955217	CHN	China	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	156	104.1403375	32.30955217	CHN	China	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	162	105.6426067	-10.4882473	CXR	Christmas Island	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	162	105.6426067	-10.4882473	CXR	Christmas Island	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	162	105.6426067	-10.4882473	CXR	Christmas Island	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	162	105.6426067	-10.4882473	CXR	Christmas Island	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	162	105.6426067	-10.4882473	CXR	Christmas Island	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	162	105.6426067	-10.4882473	CXR	Christmas Island	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	162	105.6426067	-10.4882473	CXR	Christmas Island	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	162	105.6426067	-10.4882473	CXR	Christmas Island	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	162	105.6426067	-10.4882473	CXR	Christmas Island	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	166	96.82633757	-12.18600682	CCK	Cocos (Keeling) Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	166	96.82633757	-12.18600682	CCK	Cocos (Keeling) Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	166	96.82633757	-12.18600682	CCK	Cocos (Keeling) Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	166	96.82633757	-12.18600682	CCK	Cocos (Keeling) Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	166	96.82633757	-12.18600682	CCK	Cocos (Keeling) Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	166	96.82633757	-12.18600682	CCK	Cocos (Keeling) Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	166	96.82633757	-12.18600682	CCK	Cocos (Keeling) Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	166	96.82633757	-12.18600682	CCK	Cocos (Keeling) Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	166	96.82633757	-12.18600682	CCK	Cocos (Keeling) Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	-73.07446751	3.888209046	COL	Colombia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	-73.07446751	3.888209046	COL	Colombia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	-73.07446751	3.888209046	COL	Colombia	1	PERCENT	Percentage	2010	22	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	-73.07446751	3.888209046	COL	Colombia	1	PERCENT	Percentage	2011	46	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	-73.07446751	3.888209046	COL	Colombia	1	PERCENT	Percentage	2012	84	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	-73.07446751	3.888209046	COL	Colombia	1	PERCENT	Percentage	2013	87	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	-73.07446751	3.888209046	COL	Colombia	1	PERCENT	Percentage	2014	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	-73.07446751	3.888209046	COL	Colombia	1	PERCENT	Percentage	2015	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	-73.07446751	3.888209046	COL	Colombia	1	PERCENT	Percentage	2016	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	174	43.34234565	-11.66121732	COM	Comoros	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	174	43.34234565	-11.66121732	COM	Comoros	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	174	43.34234565	-11.66121732	COM	Comoros	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	174	43.34234565	-11.66121732	COM	Comoros	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	174	43.34234565	-11.66121732	COM	Comoros	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	174	43.34234565	-11.66121732	COM	Comoros	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	174	43.34234565	-11.66121732	COM	Comoros	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	174	43.34234565	-11.66121732	COM	Comoros	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	174	43.34234565	-11.66121732	COM	Comoros	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	175	45.14015057	-12.82217691	MYT	Mayotte	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	175	45.14015057	-12.82217691	MYT	Mayotte	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	175	45.14015057	-12.82217691	MYT	Mayotte	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	175	45.14015057	-12.82217691	MYT	Mayotte	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	175	45.14015057	-12.82217691	MYT	Mayotte	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	175	45.14015057	-12.82217691	MYT	Mayotte	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	175	45.14015057	-12.82217691	MYT	Mayotte	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	175	45.14015057	-12.82217691	MYT	Mayotte	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	175	45.14015057	-12.82217691	MYT	Mayotte	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	15.22052612	-0.840544119	COG	Congo	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	15.22052612	-0.840544119	COG	Congo	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	15.22052612	-0.840544119	COG	Congo	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	15.22052612	-0.840544119	COG	Congo	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	15.22052612	-0.840544119	COG	Congo	1	PERCENT	Percentage	2012	10	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	15.22052612	-0.840544119	COG	Congo	1	PERCENT	Percentage	2013	85	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	15.22052612	-0.840544119	COG	Congo	1	PERCENT	Percentage	2014	85	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	15.22052612	-0.840544119	COG	Congo	1	PERCENT	Percentage	2015	80	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	15.22052612	-0.840544119	COG	Congo	1	PERCENT	Percentage	2016	80	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	23.65496507	-2.877154732	COD	Democratic Republic of the Congo	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	23.65496507	-2.877154732	COD	Democratic Republic of the Congo	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	23.65496507	-2.877154732	COD	Democratic Republic of the Congo	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	23.65496507	-2.877154732	COD	Democratic Republic of the Congo	1	PERCENT	Percentage	2011	9	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	23.65496507	-2.877154732	COD	Democratic Republic of the Congo	1	PERCENT	Percentage	2012	13	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	23.65496507	-2.877154732	COD	Democratic Republic of the Congo	1	PERCENT	Percentage	2013	31	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	23.65496507	-2.877154732	COD	Democratic Republic of the Congo	1	PERCENT	Percentage	2014	61	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	23.65496507	-2.877154732	COD	Democratic Republic of the Congo	1	PERCENT	Percentage	2015	73	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	23.65496507	-2.877154732	COD	Democratic Republic of the Congo	1	PERCENT	Percentage	2016	77	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	184	-159.7711391	-21.22696458	COK	Cook Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	184	-159.7711391	-21.22696458	COK	Cook Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	184	-159.7711391	-21.22696458	COK	Cook Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	184	-159.7711391	-21.22696458	COK	Cook Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	184	-159.7711391	-21.22696458	COK	Cook Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	184	-159.7711391	-21.22696458	COK	Cook Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	184	-159.7711391	-21.22696458	COK	Cook Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	184	-159.7711391	-21.22696458	COK	Cook Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	184	-159.7711391	-21.22696458	COK	Cook Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	-84.19712782	9.970998683	CRI	Costa Rica	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	-84.19712782	9.970998683	CRI	Costa Rica	1	PERCENT	Percentage	2009	48	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	-84.19712782	9.970998683	CRI	Costa Rica	1	PERCENT	Percentage	2010	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	-84.19712782	9.970998683	CRI	Costa Rica	1	PERCENT	Percentage	2011	68	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	-84.19712782	9.970998683	CRI	Costa Rica	1	PERCENT	Percentage	2012	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	-84.19712782	9.970998683	CRI	Costa Rica	1	PERCENT	Percentage	2013	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	-84.19712782	9.970998683	CRI	Costa Rica	1	PERCENT	Percentage	2014	83	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	-84.19712782	9.970998683	CRI	Costa Rica	1	PERCENT	Percentage	2015	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	-84.19712782	9.970998683	CRI	Costa Rica	1	PERCENT	Percentage	2016	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	191	17.95874553	45.45172212	HRV	Croatia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	191	17.95874553	45.45172212	HRV	Croatia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	191	17.95874553	45.45172212	HRV	Croatia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	191	17.95874553	45.45172212	HRV	Croatia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	191	17.95874553	45.45172212	HRV	Croatia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	191	17.95874553	45.45172212	HRV	Croatia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	191	17.95874553	45.45172212	HRV	Croatia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	191	17.95874553	45.45172212	HRV	Croatia	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	191	17.95874553	45.45172212	HRV	Croatia	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	192	-79.54460144	22.10030366	CUB	Cuba	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	192	-79.54460144	22.10030366	CUB	Cuba	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	192	-79.54460144	22.10030366	CUB	Cuba	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	192	-79.54460144	22.10030366	CUB	Cuba	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	192	-79.54460144	22.10030366	CUB	Cuba	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	192	-79.54460144	22.10030366	CUB	Cuba	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	192	-79.54460144	22.10030366	CUB	Cuba	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	192	-79.54460144	22.10030366	CUB	Cuba	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	192	-79.54460144	22.10030366	CUB	Cuba	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	33.22285964	35.05659437	CYP	Cyprus	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	33.22285964	35.05659437	CYP	Cyprus	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	33.22285964	35.05659437	CYP	Cyprus	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	33.22285964	35.05659437	CYP	Cyprus	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	33.22285964	35.05659437	CYP	Cyprus	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	33.22285964	35.05659437	CYP	Cyprus	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	33.22285964	35.05659437	CYP	Cyprus	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	33.22285964	35.05659437	CYP	Cyprus	1	PERCENT	Percentage	2015	81	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	33.22285964	35.05659437	CYP	Cyprus	1	PERCENT	Percentage	2016	81	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	203	15.33151382	49.73913871	CZE	Czechia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	203	15.33151382	49.73913871	CZE	Czechia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	203	15.33151382	49.73913871	CZE	Czechia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	203	15.33151382	49.73913871	CZE	Czechia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	203	15.33151382	49.73913871	CZE	Czechia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	203	15.33151382	49.73913871	CZE	Czechia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	203	15.33151382	49.73913871	CZE	Czechia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	203	15.33151382	49.73913871	CZE	Czechia	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	203	15.33151382	49.73913871	CZE	Czechia	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	2.339933594	9.65401646	BEN	Benin	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	2.339933594	9.65401646	BEN	Benin	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	2.339933594	9.65401646	BEN	Benin	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	2.339933594	9.65401646	BEN	Benin	1	PERCENT	Percentage	2011	36	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	2.339933594	9.65401646	BEN	Benin	1	PERCENT	Percentage	2012	67	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	2.339933594	9.65401646	BEN	Benin	1	PERCENT	Percentage	2013	70	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	2.339933594	9.65401646	BEN	Benin	1	PERCENT	Percentage	2014	71	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	2.339933594	9.65401646	BEN	Benin	1	PERCENT	Percentage	2015	75	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	2.339933594	9.65401646	BEN	Benin	1	PERCENT	Percentage	2016	75	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	9.326571283	56.03829721	DNK	Denmark	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	9.326571283	56.03829721	DNK	Denmark	1	PERCENT	Percentage	2009	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	9.326571283	56.03829721	DNK	Denmark	1	PERCENT	Percentage	2010	88	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	9.326571283	56.03829721	DNK	Denmark	1	PERCENT	Percentage	2011	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	9.326571283	56.03829721	DNK	Denmark	1	PERCENT	Percentage	2012	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	9.326571283	56.03829721	DNK	Denmark	1	PERCENT	Percentage	2013	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	9.326571283	56.03829721	DNK	Denmark	1	PERCENT	Percentage	2014	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	9.326571283	56.03829721	DNK	Denmark	1	PERCENT	Percentage	2015	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	9.326571283	56.03829721	DNK	Denmark	1	PERCENT	Percentage	2016	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	212	-61.3493756	15.43391378	DMA	Dominica	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	212	-61.3493756	15.43391378	DMA	Dominica	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	212	-61.3493756	15.43391378	DMA	Dominica	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	212	-61.3493756	15.43391378	DMA	Dominica	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	212	-61.3493756	15.43391378	DMA	Dominica	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	212	-61.3493756	15.43391378	DMA	Dominica	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	212	-61.3493756	15.43391378	DMA	Dominica	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	212	-61.3493756	15.43391378	DMA	Dominica	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	212	-61.3493756	15.43391378	DMA	Dominica	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	-70.49847576	18.89832088	DOM	Dominican Republic	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	-70.49847576	18.89832088	DOM	Dominican Republic	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	-70.49847576	18.89832088	DOM	Dominican Republic	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	-70.49847576	18.89832088	DOM	Dominican Republic	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	-70.49847576	18.89832088	DOM	Dominican Republic	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	-70.49847576	18.89832088	DOM	Dominican Republic	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	-70.49847576	18.89832088	DOM	Dominican Republic	1	PERCENT	Percentage	2014	27	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	-70.49847576	18.89832088	DOM	Dominican Republic	1	PERCENT	Percentage	2015	22	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	-70.49847576	18.89832088	DOM	Dominican Republic	1	PERCENT	Percentage	2016	30	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	-78.37005241	-1.447785891	ECU	Ecuador	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	-78.37005241	-1.447785891	ECU	Ecuador	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	-78.37005241	-1.447785891	ECU	Ecuador	1	PERCENT	Percentage	2010	17	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	-78.37005241	-1.447785891	ECU	Ecuador	1	PERCENT	Percentage	2011	71	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	-78.37005241	-1.447785891	ECU	Ecuador	1	PERCENT	Percentage	2012	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	-78.37005241	-1.447785891	ECU	Ecuador	1	PERCENT	Percentage	2013	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	-78.37005241	-1.447785891	ECU	Ecuador	1	PERCENT	Percentage	2014	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	-78.37005241	-1.447785891	ECU	Ecuador	1	PERCENT	Percentage	2015	81	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	-78.37005241	-1.447785891	ECU	Ecuador	1	PERCENT	Percentage	2016	84	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	-88.86862995	13.73603564	SLV	El Salvador	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	-88.86862995	13.73603564	SLV	El Salvador	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	-88.86862995	13.73603564	SLV	El Salvador	1	PERCENT	Percentage	2010	69	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	-88.86862995	13.73603564	SLV	El Salvador	1	PERCENT	Percentage	2011	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	-88.86862995	13.73603564	SLV	El Salvador	1	PERCENT	Percentage	2012	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	-88.86862995	13.73603564	SLV	El Salvador	1	PERCENT	Percentage	2013	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	-88.86862995	13.73603564	SLV	El Salvador	1	PERCENT	Percentage	2014	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	-88.86862995	13.73603564	SLV	El Salvador	1	PERCENT	Percentage	2015	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	-88.86862995	13.73603564	SLV	El Salvador	1	PERCENT	Percentage	2016	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	226	10.46535826	1.565792376	GNQ	Equatorial Guinea	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	226	10.46535826	1.565792376	GNQ	Equatorial Guinea	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	226	10.46535826	1.565792376	GNQ	Equatorial Guinea	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	226	10.46535826	1.565792376	GNQ	Equatorial Guinea	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	226	10.46535826	1.565792376	GNQ	Equatorial Guinea	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	226	10.46535826	1.565792376	GNQ	Equatorial Guinea	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	226	10.46535826	1.565792376	GNQ	Equatorial Guinea	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	226	10.46535826	1.565792376	GNQ	Equatorial Guinea	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	226	10.46535826	1.565792376	GNQ	Equatorial Guinea	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	39.63505296	8.631223181	ETH	Ethiopia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	39.63505296	8.631223181	ETH	Ethiopia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	39.63505296	8.631223181	ETH	Ethiopia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	39.63505296	8.631223181	ETH	Ethiopia	1	PERCENT	Percentage	2011	12	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	39.63505296	8.631223181	ETH	Ethiopia	1	PERCENT	Percentage	2012	38	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	39.63505296	8.631223181	ETH	Ethiopia	1	PERCENT	Percentage	2013	63	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	39.63505296	8.631223181	ETH	Ethiopia	1	PERCENT	Percentage	2014	76	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	39.63505296	8.631223181	ETH	Ethiopia	1	PERCENT	Percentage	2015	76	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	39.63505296	8.631223181	ETH	Ethiopia	1	PERCENT	Percentage	2016	76	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	232	38.11074289	16.12894644	ERI	Eritrea	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	232	38.11074289	16.12894644	ERI	Eritrea	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	232	38.11074289	16.12894644	ERI	Eritrea	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	232	38.11074289	16.12894644	ERI	Eritrea	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	232	38.11074289	16.12894644	ERI	Eritrea	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	232	38.11074289	16.12894644	ERI	Eritrea	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	232	38.11074289	16.12894644	ERI	Eritrea	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	232	38.11074289	16.12894644	ERI	Eritrea	1	PERCENT	Percentage	2015	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	232	38.11074289	16.12894644	ERI	Eritrea	1	PERCENT	Percentage	2016	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	233	25.84093481	58.68487172	EST	Estonia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	233	25.84093481	58.68487172	EST	Estonia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	233	25.84093481	58.68487172	EST	Estonia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	233	25.84093481	58.68487172	EST	Estonia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	233	25.84093481	58.68487172	EST	Estonia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	233	25.84093481	58.68487172	EST	Estonia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	233	25.84093481	58.68487172	EST	Estonia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	233	25.84093481	58.68487172	EST	Estonia	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	233	25.84093481	58.68487172	EST	Estonia	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	234	-7.122044325	62.21228119	FRO	Faroe Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	234	-7.122044325	62.21228119	FRO	Faroe Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	234	-7.122044325	62.21228119	FRO	Faroe Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	234	-7.122044325	62.21228119	FRO	Faroe Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	234	-7.122044325	62.21228119	FRO	Faroe Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	234	-7.122044325	62.21228119	FRO	Faroe Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	234	-7.122044325	62.21228119	FRO	Faroe Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	234	-7.122044325	62.21228119	FRO	Faroe Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	234	-7.122044325	62.21228119	FRO	Faroe Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	238	-58.75246778	-51.74562601	FLK	Falkland Islands (Malvinas)	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	238	-58.75246778	-51.74562601	FLK	Falkland Islands (Malvinas)	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	238	-58.75246778	-51.74562601	FLK	Falkland Islands (Malvinas)	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	238	-58.75246778	-51.74562601	FLK	Falkland Islands (Malvinas)	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	238	-58.75246778	-51.74562601	FLK	Falkland Islands (Malvinas)	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	238	-58.75246778	-51.74562601	FLK	Falkland Islands (Malvinas)	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	238	-58.75246778	-51.74562601	FLK	Falkland Islands (Malvinas)	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	238	-58.75246778	-51.74562601	FLK	Falkland Islands (Malvinas)	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	238	-58.75246778	-51.74562601	FLK	Falkland Islands (Malvinas)	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	239	-36.90662765	-54.20736749	SGS	South Georgia and the South Sandwich Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	239	-36.90662765	-54.20736749	SGS	South Georgia and the South Sandwich Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	239	-36.90662765	-54.20736749	SGS	South Georgia and the South Sandwich Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	239	-36.90662765	-54.20736749	SGS	South Georgia and the South Sandwich Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	239	-36.90662765	-54.20736749	SGS	South Georgia and the South Sandwich Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	239	-36.90662765	-54.20736749	SGS	South Georgia and the South Sandwich Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	239	-36.90662765	-54.20736749	SGS	South Georgia and the South Sandwich Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	239	-36.90662765	-54.20736749	SGS	South Georgia and the South Sandwich Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	239	-36.90662765	-54.20736749	SGS	South Georgia and the South Sandwich Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	177.9660884	-17.83301566	FJI	Fiji	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	177.9660884	-17.83301566	FJI	Fiji	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	177.9660884	-17.83301566	FJI	Fiji	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	177.9660884	-17.83301566	FJI	Fiji	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	177.9660884	-17.83301566	FJI	Fiji	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	177.9660884	-17.83301566	FJI	Fiji	1	PERCENT	Percentage	2013	87	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	177.9660884	-17.83301566	FJI	Fiji	1	PERCENT	Percentage	2014	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	177.9660884	-17.83301566	FJI	Fiji	1	PERCENT	Percentage	2015	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	177.9660884	-17.83301566	FJI	Fiji	1	PERCENT	Percentage	2016	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	23.308447	61.91586738	FIN	Finland	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	23.308447	61.91586738	FIN	Finland	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	23.308447	61.91586738	FIN	Finland	1	PERCENT	Percentage	2010	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	23.308447	61.91586738	FIN	Finland	1	PERCENT	Percentage	2011	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	23.308447	61.91586738	FIN	Finland	1	PERCENT	Percentage	2012	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	23.308447	61.91586738	FIN	Finland	1	PERCENT	Percentage	2013	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	23.308447	61.91586738	FIN	Finland	1	PERCENT	Percentage	2014	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	23.308447	61.91586738	FIN	Finland	1	PERCENT	Percentage	2015	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	23.308447	61.91586738	FIN	Finland	1	PERCENT	Percentage	2016	87	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	248	19.80945969	60.1544901	ALA	Åland Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	248	19.80945969	60.1544901	ALA	Åland Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	248	19.80945969	60.1544901	ALA	Åland Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	248	19.80945969	60.1544901	ALA	Åland Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	248	19.80945969	60.1544901	ALA	Åland Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	248	19.80945969	60.1544901	ALA	Åland Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	248	19.80945969	60.1544901	ALA	Åland Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	248	19.80945969	60.1544901	ALA	Åland Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	248	19.80945969	60.1544901	ALA	Åland Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	2.457288129	46.62660861	FRA	France	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	2.457288129	46.62660861	FRA	France	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	2.457288129	46.62660861	FRA	France	1	PERCENT	Percentage	2010	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	2.457288129	46.62660861	FRA	France	1	PERCENT	Percentage	2011	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	2.457288129	46.62660861	FRA	France	1	PERCENT	Percentage	2012	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	2.457288129	46.62660861	FRA	France	1	PERCENT	Percentage	2013	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	2.457288129	46.62660861	FRA	France	1	PERCENT	Percentage	2014	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	2.457288129	46.62660861	FRA	France	1	PERCENT	Percentage	2015	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	2.457288129	46.62660861	FRA	France	1	PERCENT	Percentage	2016	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	254	-53.23619089	3.922673437	GUF	French Guiana	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	254	-53.23619089	3.922673437	GUF	French Guiana	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	254	-53.23619089	3.922673437	GUF	French Guiana	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	254	-53.23619089	3.922673437	GUF	French Guiana	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	254	-53.23619089	3.922673437	GUF	French Guiana	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	254	-53.23619089	3.922673437	GUF	French Guiana	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	254	-53.23619089	3.922673437	GUF	French Guiana	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	254	-53.23619089	3.922673437	GUF	French Guiana	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	254	-53.23619089	3.922673437	GUF	French Guiana	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	258	-149.4052367	-17.67709294	PYF	French Polynesia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	258	-149.4052367	-17.67709294	PYF	French Polynesia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	258	-149.4052367	-17.67709294	PYF	French Polynesia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	258	-149.4052367	-17.67709294	PYF	French Polynesia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	258	-149.4052367	-17.67709294	PYF	French Polynesia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	258	-149.4052367	-17.67709294	PYF	French Polynesia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	258	-149.4052367	-17.67709294	PYF	French Polynesia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	258	-149.4052367	-17.67709294	PYF	French Polynesia	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	258	-149.4052367	-17.67709294	PYF	French Polynesia	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	260	69.64849091	-49.6068576	ATF	French Southern Territories	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	260	69.64849091	-49.6068576	ATF	French Southern Territories	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	260	69.64849091	-49.6068576	ATF	French Southern Territories	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	260	69.64849091	-49.6068576	ATF	French Southern Territories	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	260	69.64849091	-49.6068576	ATF	French Southern Territories	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	260	69.64849091	-49.6068576	ATF	French Southern Territories	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	260	69.64849091	-49.6068576	ATF	French Southern Territories	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	260	69.64849091	-49.6068576	ATF	French Southern Territories	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	260	69.64849091	-49.6068576	ATF	French Southern Territories	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	42.18274707	11.56004161	DJI	Djibouti	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	42.18274707	11.56004161	DJI	Djibouti	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	42.18274707	11.56004161	DJI	Djibouti	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	42.18274707	11.56004161	DJI	Djibouti	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	42.18274707	11.56004161	DJI	Djibouti	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	42.18274707	11.56004161	DJI	Djibouti	1	PERCENT	Percentage	2013	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	42.18274707	11.56004161	DJI	Djibouti	1	PERCENT	Percentage	2014	78	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	42.18274707	11.56004161	DJI	Djibouti	1	PERCENT	Percentage	2015	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	42.18274707	11.56004161	DJI	Djibouti	1	PERCENT	Percentage	2016	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	266	11.78727747	-0.60687619	GAB	Gabon	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	266	11.78727747	-0.60687619	GAB	Gabon	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	266	11.78727747	-0.60687619	GAB	Gabon	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	266	11.78727747	-0.60687619	GAB	Gabon	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	266	11.78727747	-0.60687619	GAB	Gabon	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	266	11.78727747	-0.60687619	GAB	Gabon	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	266	11.78727747	-0.60687619	GAB	Gabon	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	266	11.78727747	-0.60687619	GAB	Gabon	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	266	11.78727747	-0.60687619	GAB	Gabon	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	43.3713615	42.04813028	GEO	Georgia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	43.3713615	42.04813028	GEO	Georgia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	43.3713615	42.04813028	GEO	Georgia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	43.3713615	42.04813028	GEO	Georgia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	43.3713615	42.04813028	GEO	Georgia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	43.3713615	42.04813028	GEO	Georgia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	43.3713615	42.04813028	GEO	Georgia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	43.3713615	42.04813028	GEO	Georgia	1	PERCENT	Percentage	2015	16	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	43.3713615	42.04813028	GEO	Georgia	1	PERCENT	Percentage	2016	75	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	-15.39944785	13.45295927	GMB	Gambia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	-15.39944785	13.45295927	GMB	Gambia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	-15.39944785	13.45295927	GMB	Gambia	1	PERCENT	Percentage	2010	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	-15.39944785	13.45295927	GMB	Gambia	1	PERCENT	Percentage	2011	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	-15.39944785	13.45295927	GMB	Gambia	1	PERCENT	Percentage	2012	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	-15.39944785	13.45295927	GMB	Gambia	1	PERCENT	Percentage	2013	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	-15.39944785	13.45295927	GMB	Gambia	1	PERCENT	Percentage	2014	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	-15.39944785	13.45295927	GMB	Gambia	1	PERCENT	Percentage	2015	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	-15.39944785	13.45295927	GMB	Gambia	1	PERCENT	Percentage	2016	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	35.25694122	31.94347933	PSE	State of Palestine	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	35.25694122	31.94347933	PSE	State of Palestine	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	35.25694122	31.94347933	PSE	State of Palestine	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	35.25694122	31.94347933	PSE	State of Palestine	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	35.25694122	31.94347933	PSE	State of Palestine	1	PERCENT	Percentage	2012	25	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	35.25694122	31.94347933	PSE	State of Palestine	1	PERCENT	Percentage	2013	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	35.25694122	31.94347933	PSE	State of Palestine	1	PERCENT	Percentage	2014	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	35.25694122	31.94347933	PSE	State of Palestine	1	PERCENT	Percentage	2015	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	35.25694122	31.94347933	PSE	State of Palestine	1	PERCENT	Percentage	2016	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	10.3806066	51.08862743	DEU	Germany	1	PERCENT	Percentage	2008	68	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	10.3806066	51.08862743	DEU	Germany	1	PERCENT	Percentage	2009	85	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	10.3806066	51.08862743	DEU	Germany	1	PERCENT	Percentage	2010	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	10.3806066	51.08862743	DEU	Germany	1	PERCENT	Percentage	2011	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	10.3806066	51.08862743	DEU	Germany	1	PERCENT	Percentage	2012	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	10.3806066	51.08862743	DEU	Germany	1	PERCENT	Percentage	2013	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	10.3806066	51.08862743	DEU	Germany	1	PERCENT	Percentage	2014	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	10.3806066	51.08862743	DEU	Germany	1	PERCENT	Percentage	2015	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	10.3806066	51.08862743	DEU	Germany	1	PERCENT	Percentage	2016	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	-1.205623522	7.964825185	GHA	Ghana	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	-1.205623522	7.964825185	GHA	Ghana	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	-1.205623522	7.964825185	GHA	Ghana	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	-1.205623522	7.964825185	GHA	Ghana	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	-1.205623522	7.964825185	GHA	Ghana	1	PERCENT	Percentage	2012	43	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	-1.205623522	7.964825185	GHA	Ghana	1	PERCENT	Percentage	2013	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	-1.205623522	7.964825185	GHA	Ghana	1	PERCENT	Percentage	2014	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	-1.205623522	7.964825185	GHA	Ghana	1	PERCENT	Percentage	2015	88	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	-1.205623522	7.964825185	GHA	Ghana	1	PERCENT	Percentage	2016	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	292	-5.347561686	36.13895036	GIB	Gibraltar	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	292	-5.347561686	36.13895036	GIB	Gibraltar	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	292	-5.347561686	36.13895036	GIB	Gibraltar	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	292	-5.347561686	36.13895036	GIB	Gibraltar	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	292	-5.347561686	36.13895036	GIB	Gibraltar	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	292	-5.347561686	36.13895036	GIB	Gibraltar	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	292	-5.347561686	36.13895036	GIB	Gibraltar	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	292	-5.347561686	36.13895036	GIB	Gibraltar	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	292	-5.347561686	36.13895036	GIB	Gibraltar	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	-157.5643005	1.768837732	KIR	Kiribati	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	-157.5643005	1.768837732	KIR	Kiribati	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	-157.5643005	1.768837732	KIR	Kiribati	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	-157.5643005	1.768837732	KIR	Kiribati	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	-157.5643005	1.768837732	KIR	Kiribati	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	-157.5643005	1.768837732	KIR	Kiribati	1	PERCENT	Percentage	2013	40	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	-157.5643005	1.768837732	KIR	Kiribati	1	PERCENT	Percentage	2014	57	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	-157.5643005	1.768837732	KIR	Kiribati	1	PERCENT	Percentage	2015	74	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	-157.5643005	1.768837732	KIR	Kiribati	1	PERCENT	Percentage	2016	79	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	22.58307827	39.47301873	GRC	Greece	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	22.58307827	39.47301873	GRC	Greece	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	22.58307827	39.47301873	GRC	Greece	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	22.58307827	39.47301873	GRC	Greece	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	22.58307827	39.47301873	GRC	Greece	1	PERCENT	Percentage	2012	32	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	22.58307827	39.47301873	GRC	Greece	1	PERCENT	Percentage	2013	32	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	22.58307827	39.47301873	GRC	Greece	1	PERCENT	Percentage	2014	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	22.58307827	39.47301873	GRC	Greece	1	PERCENT	Percentage	2015	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	22.58307827	39.47301873	GRC	Greece	1	PERCENT	Percentage	2016	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	304	-41.39371316	74.75625681	GRL	Greenland	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	304	-41.39371316	74.75625681	GRL	Greenland	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	304	-41.39371316	74.75625681	GRL	Greenland	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	304	-41.39371316	74.75625681	GRL	Greenland	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	304	-41.39371316	74.75625681	GRL	Greenland	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	304	-41.39371316	74.75625681	GRL	Greenland	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	304	-41.39371316	74.75625681	GRL	Greenland	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	304	-41.39371316	74.75625681	GRL	Greenland	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	304	-41.39371316	74.75625681	GRL	Greenland	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	308	-61.68248568	12.11238395	GRD	Grenada	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	308	-61.68248568	12.11238395	GRD	Grenada	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	308	-61.68248568	12.11238395	GRD	Grenada	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	308	-61.68248568	12.11238395	GRD	Grenada	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	308	-61.68248568	12.11238395	GRD	Grenada	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	308	-61.68248568	12.11238395	GRD	Grenada	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	308	-61.68248568	12.11238395	GRD	Grenada	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	308	-61.68248568	12.11238395	GRD	Grenada	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	308	-61.68248568	12.11238395	GRD	Grenada	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	312	-61.64762115	16.14416917	GLP	Guadeloupe	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	312	-61.64762115	16.14416917	GLP	Guadeloupe	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	312	-61.64762115	16.14416917	GLP	Guadeloupe	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	312	-61.64762115	16.14416917	GLP	Guadeloupe	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	312	-61.64762115	16.14416917	GLP	Guadeloupe	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	312	-61.64762115	16.14416917	GLP	Guadeloupe	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	312	-61.64762115	16.14416917	GLP	Guadeloupe	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	312	-61.64762115	16.14416917	GLP	Guadeloupe	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	312	-61.64762115	16.14416917	GLP	Guadeloupe	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	316	144.7029305	13.35485404	GUM	Guam	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	316	144.7029305	13.35485404	GUM	Guam	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	316	144.7029305	13.35485404	GUM	Guam	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	316	144.7029305	13.35485404	GUM	Guam	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	316	144.7029305	13.35485404	GUM	Guam	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	316	144.7029305	13.35485404	GUM	Guam	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	316	144.7029305	13.35485404	GUM	Guam	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	316	144.7029305	13.35485404	GUM	Guam	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	316	144.7029305	13.35485404	GUM	Guam	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	-91.2312746	15.00273719	GTM	Guatemala	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	-91.2312746	15.00273719	GTM	Guatemala	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	-91.2312746	15.00273719	GTM	Guatemala	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	-91.2312746	15.00273719	GTM	Guatemala	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	-91.2312746	15.00273719	GTM	Guatemala	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	-91.2312746	15.00273719	GTM	Guatemala	1	PERCENT	Percentage	2013	24	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	-91.2312746	15.00273719	GTM	Guatemala	1	PERCENT	Percentage	2014	51	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	-91.2312746	15.00273719	GTM	Guatemala	1	PERCENT	Percentage	2015	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	-91.2312746	15.00273719	GTM	Guatemala	1	PERCENT	Percentage	2016	81	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	324	-11.28173419	11.00210343	GIN	Guinea	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	324	-11.28173419	11.00210343	GIN	Guinea	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	324	-11.28173419	11.00210343	GIN	Guinea	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	324	-11.28173419	11.00210343	GIN	Guinea	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	324	-11.28173419	11.00210343	GIN	Guinea	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	324	-11.28173419	11.00210343	GIN	Guinea	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	324	-11.28173419	11.00210343	GIN	Guinea	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	324	-11.28173419	11.00210343	GIN	Guinea	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	324	-11.28173419	11.00210343	GIN	Guinea	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	-58.97322037	4.788012784	GUY	Guyana	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	-58.97322037	4.788012784	GUY	Guyana	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	-58.97322037	4.788012784	GUY	Guyana	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	-58.97322037	4.788012784	GUY	Guyana	1	PERCENT	Percentage	2011	50	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	-58.97322037	4.788012784	GUY	Guyana	1	PERCENT	Percentage	2012	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	-58.97322037	4.788012784	GUY	Guyana	1	PERCENT	Percentage	2013	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	-58.97322037	4.788012784	GUY	Guyana	1	PERCENT	Percentage	2014	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	-58.97322037	4.788012784	GUY	Guyana	1	PERCENT	Percentage	2015	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	-58.97322037	4.788012784	GUY	Guyana	1	PERCENT	Percentage	2016	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	332	-72.33640958	18.40426539	HTI	Haiti	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	332	-72.33640958	18.40426539	HTI	Haiti	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	332	-72.33640958	18.40426539	HTI	Haiti	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	332	-72.33640958	18.40426539	HTI	Haiti	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	332	-72.33640958	18.40426539	HTI	Haiti	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	332	-72.33640958	18.40426539	HTI	Haiti	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	332	-72.33640958	18.40426539	HTI	Haiti	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	332	-72.33640958	18.40426539	HTI	Haiti	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	332	-72.33640958	18.40426539	HTI	Haiti	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	334	73.52633626	-53.09106147	HMD	Heard Island and McDonald Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	334	73.52633626	-53.09106147	HMD	Heard Island and McDonald Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	334	73.52633626	-53.09106147	HMD	Heard Island and McDonald Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	334	73.52633626	-53.09106147	HMD	Heard Island and McDonald Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	334	73.52633626	-53.09106147	HMD	Heard Island and McDonald Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	334	73.52633626	-53.09106147	HMD	Heard Island and McDonald Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	334	73.52633626	-53.09106147	HMD	Heard Island and McDonald Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	334	73.52633626	-53.09106147	HMD	Heard Island and McDonald Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	334	73.52633626	-53.09106147	HMD	Heard Island and McDonald Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	336	12.45315803	41.90343751	VAT	Holy See	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	336	12.45315803	41.90343751	VAT	Holy See	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	336	12.45315803	41.90343751	VAT	Holy See	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	336	12.45315803	41.90343751	VAT	Holy See	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	336	12.45315803	41.90343751	VAT	Holy See	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	336	12.45315803	41.90343751	VAT	Holy See	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	336	12.45315803	41.90343751	VAT	Holy See	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	336	12.45315803	41.90343751	VAT	Holy See	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	336	12.45315803	41.90343751	VAT	Holy See	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	-86.59974381	14.82243161	HND	Honduras	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	-86.59974381	14.82243161	HND	Honduras	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	-86.59974381	14.82243161	HND	Honduras	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	-86.59974381	14.82243161	HND	Honduras	1	PERCENT	Percentage	2011	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	-86.59974381	14.82243161	HND	Honduras	1	PERCENT	Percentage	2012	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	-86.59974381	14.82243161	HND	Honduras	1	PERCENT	Percentage	2013	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	-86.59974381	14.82243161	HND	Honduras	1	PERCENT	Percentage	2014	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	-86.59974381	14.82243161	HND	Honduras	1	PERCENT	Percentage	2015	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	-86.59974381	14.82243161	HND	Honduras	1	PERCENT	Percentage	2016	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	344	114.0266445	22.41749934	HKG	China, Hong Kong Special Administrative Region	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	344	114.0266445	22.41749934	HKG	China, Hong Kong Special Administrative Region	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	344	114.0266445	22.41749934	HKG	China, Hong Kong Special Administrative Region	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	344	114.0266445	22.41749934	HKG	China, Hong Kong Special Administrative Region	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	344	114.0266445	22.41749934	HKG	China, Hong Kong Special Administrative Region	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	344	114.0266445	22.41749934	HKG	China, Hong Kong Special Administrative Region	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	344	114.0266445	22.41749934	HKG	China, Hong Kong Special Administrative Region	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	344	114.0266445	22.41749934	HKG	China, Hong Kong Special Administrative Region	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	344	114.0266445	22.41749934	HKG	China, Hong Kong Special Administrative Region	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	19.41221519	47.1651448	HUN	Hungary	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	19.41221519	47.1651448	HUN	Hungary	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	19.41221519	47.1651448	HUN	Hungary	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	19.41221519	47.1651448	HUN	Hungary	1	PERCENT	Percentage	2011	84	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	19.41221519	47.1651448	HUN	Hungary	1	PERCENT	Percentage	2012	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	19.41221519	47.1651448	HUN	Hungary	1	PERCENT	Percentage	2013	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	19.41221519	47.1651448	HUN	Hungary	1	PERCENT	Percentage	2014	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	19.41221519	47.1651448	HUN	Hungary	1	PERCENT	Percentage	2015	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	19.41221519	47.1651448	HUN	Hungary	1	PERCENT	Percentage	2016	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	-19.02116966	64.79134763	ISL	Iceland	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	-19.02116966	64.79134763	ISL	Iceland	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	-19.02116966	64.79134763	ISL	Iceland	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	-19.02116966	64.79134763	ISL	Iceland	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	-19.02116966	64.79134763	ISL	Iceland	1	PERCENT	Percentage	2012	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	-19.02116966	64.79134763	ISL	Iceland	1	PERCENT	Percentage	2013	88	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	-19.02116966	64.79134763	ISL	Iceland	1	PERCENT	Percentage	2014	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	-19.02116966	64.79134763	ISL	Iceland	1	PERCENT	Percentage	2015	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	-19.02116966	64.79134763	ISL	Iceland	1	PERCENT	Percentage	2016	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	356	79.3608464	22.34642074	IND	India	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	356	79.3608464	22.34642074	IND	India	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	356	79.3608464	22.34642074	IND	India	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	356	79.3608464	22.34642074	IND	India	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	356	79.3608464	22.34642074	IND	India	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	356	79.3608464	22.34642074	IND	India	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	356	79.3608464	22.34642074	IND	India	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	356	79.3608464	22.34642074	IND	India	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	356	79.3608464	22.34642074	IND	India	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	360	113.9174	-0.994582204	IDN	Indonesia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	360	113.9174	-0.994582204	IDN	Indonesia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	360	113.9174	-0.994582204	IDN	Indonesia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	360	113.9174	-0.994582204	IDN	Indonesia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	360	113.9174	-0.994582204	IDN	Indonesia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	360	113.9174	-0.994582204	IDN	Indonesia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	360	113.9174	-0.994582204	IDN	Indonesia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	360	113.9174	-0.994582204	IDN	Indonesia	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	360	113.9174	-0.994582204	IDN	Indonesia	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	364	54.19766348	32.74370885	IRN	Iran (Islamic Republic of)	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	364	54.19766348	32.74370885	IRN	Iran (Islamic Republic of)	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	364	54.19766348	32.74370885	IRN	Iran (Islamic Republic of)	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	364	54.19766348	32.74370885	IRN	Iran (Islamic Republic of)	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	364	54.19766348	32.74370885	IRN	Iran (Islamic Republic of)	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	364	54.19766348	32.74370885	IRN	Iran (Islamic Republic of)	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	364	54.19766348	32.74370885	IRN	Iran (Islamic Republic of)	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	364	54.19766348	32.74370885	IRN	Iran (Islamic Republic of)	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	364	54.19766348	32.74370885	IRN	Iran (Islamic Republic of)	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	368	43.76606267	33.05013795	IRQ	Iraq	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	368	43.76606267	33.05013795	IRQ	Iraq	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	368	43.76606267	33.05013795	IRQ	Iraq	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	368	43.76606267	33.05013795	IRQ	Iraq	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	368	43.76606267	33.05013795	IRQ	Iraq	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	368	43.76606267	33.05013795	IRQ	Iraq	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	368	43.76606267	33.05013795	IRQ	Iraq	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	368	43.76606267	33.05013795	IRQ	Iraq	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	368	43.76606267	33.05013795	IRQ	Iraq	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	-7.121425272	53.25274054	IRL	Ireland	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	-7.121425272	53.25274054	IRL	Ireland	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	-7.121425272	53.25274054	IRL	Ireland	1	PERCENT	Percentage	2010	43	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	-7.121425272	53.25274054	IRL	Ireland	1	PERCENT	Percentage	2011	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	-7.121425272	53.25274054	IRL	Ireland	1	PERCENT	Percentage	2012	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	-7.121425272	53.25274054	IRL	Ireland	1	PERCENT	Percentage	2013	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	-7.121425272	53.25274054	IRL	Ireland	1	PERCENT	Percentage	2014	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	-7.121425272	53.25274054	IRL	Ireland	1	PERCENT	Percentage	2015	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	-7.121425272	53.25274054	IRL	Ireland	1	PERCENT	Percentage	2016	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	34.62277992	31.06164552	ISR	Israel	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	34.62277992	31.06164552	ISR	Israel	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	34.62277992	31.06164552	ISR	Israel	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	34.62277992	31.06164552	ISR	Israel	1	PERCENT	Percentage	2011	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	34.62277992	31.06164552	ISR	Israel	1	PERCENT	Percentage	2012	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	34.62277992	31.06164552	ISR	Israel	1	PERCENT	Percentage	2013	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	34.62277992	31.06164552	ISR	Israel	1	PERCENT	Percentage	2014	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	34.62277992	31.06164552	ISR	Israel	1	PERCENT	Percentage	2015	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	34.62277992	31.06164552	ISR	Israel	1	PERCENT	Percentage	2016	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	12.57022427	42.79917282	ITA	Italy	1	PERCENT	Percentage	2008	60	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	12.57022427	42.79917282	ITA	Italy	1	PERCENT	Percentage	2009	66	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	12.57022427	42.79917282	ITA	Italy	1	PERCENT	Percentage	2010	71	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	12.57022427	42.79917282	ITA	Italy	1	PERCENT	Percentage	2011	76	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	12.57022427	42.79917282	ITA	Italy	1	PERCENT	Percentage	2012	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	12.57022427	42.79917282	ITA	Italy	1	PERCENT	Percentage	2013	87	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	12.57022427	42.79917282	ITA	Italy	1	PERCENT	Percentage	2014	87	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	12.57022427	42.79917282	ITA	Italy	1	PERCENT	Percentage	2015	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	12.57022427	42.79917282	ITA	Italy	1	PERCENT	Percentage	2016	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	-5.552690016	7.62211586	CIV	Côte d'Ivoire	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	-5.552690016	7.62211586	CIV	Côte d'Ivoire	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	-5.552690016	7.62211586	CIV	Côte d'Ivoire	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	-5.552690016	7.62211586	CIV	Côte d'Ivoire	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	-5.552690016	7.62211586	CIV	Côte d'Ivoire	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	-5.552690016	7.62211586	CIV	Côte d'Ivoire	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	-5.552690016	7.62211586	CIV	Côte d'Ivoire	1	PERCENT	Percentage	2014	2	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	-5.552690016	7.62211586	CIV	Côte d'Ivoire	1	PERCENT	Percentage	2015	72	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	-5.552690016	7.62211586	CIV	Côte d'Ivoire	1	PERCENT	Percentage	2016	83	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	388	-77.31068409	18.15616857	JAM	Jamaica	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	388	-77.31068409	18.15616857	JAM	Jamaica	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	388	-77.31068409	18.15616857	JAM	Jamaica	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	388	-77.31068409	18.15616857	JAM	Jamaica	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	388	-77.31068409	18.15616857	JAM	Jamaica	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	388	-77.31068409	18.15616857	JAM	Jamaica	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	388	-77.31068409	18.15616857	JAM	Jamaica	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	388	-77.31068409	18.15616857	JAM	Jamaica	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	388	-77.31068409	18.15616857	JAM	Jamaica	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	139.2716103	36.6554539	JPN	Japan	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	139.2716103	36.6554539	JPN	Japan	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	139.2716103	36.6554539	JPN	Japan	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	139.2716103	36.6554539	JPN	Japan	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	139.2716103	36.6554539	JPN	Japan	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	139.2716103	36.6554539	JPN	Japan	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	139.2716103	36.6554539	JPN	Japan	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	139.2716103	36.6554539	JPN	Japan	1	PERCENT	Percentage	2015	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	139.2716103	36.6554539	JPN	Japan	1	PERCENT	Percentage	2016	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	66.65359159	48.01963494	KAZ	Kazakhstan	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	66.65359159	48.01963494	KAZ	Kazakhstan	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	66.65359159	48.01963494	KAZ	Kazakhstan	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	66.65359159	48.01963494	KAZ	Kazakhstan	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	66.65359159	48.01963494	KAZ	Kazakhstan	1	PERCENT	Percentage	2012	37	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	66.65359159	48.01963494	KAZ	Kazakhstan	1	PERCENT	Percentage	2013	52	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	66.65359159	48.01963494	KAZ	Kazakhstan	1	PERCENT	Percentage	2014	58	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	66.65359159	48.01963494	KAZ	Kazakhstan	1	PERCENT	Percentage	2015	74	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	66.65359159	48.01963494	KAZ	Kazakhstan	1	PERCENT	Percentage	2016	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	400	37.13024774	30.65365973	JOR	Jordan	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	400	37.13024774	30.65365973	JOR	Jordan	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	400	37.13024774	30.65365973	JOR	Jordan	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	400	37.13024774	30.65365973	JOR	Jordan	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	400	37.13024774	30.65365973	JOR	Jordan	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	400	37.13024774	30.65365973	JOR	Jordan	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	400	37.13024774	30.65365973	JOR	Jordan	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	400	37.13024774	30.65365973	JOR	Jordan	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	400	37.13024774	30.65365973	JOR	Jordan	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	37.86096816	0.534797278	KEN	Kenya	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	37.86096816	0.534797278	KEN	Kenya	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	37.86096816	0.534797278	KEN	Kenya	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	37.86096816	0.534797278	KEN	Kenya	1	PERCENT	Percentage	2011	85	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	37.86096816	0.534797278	KEN	Kenya	1	PERCENT	Percentage	2012	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	37.86096816	0.534797278	KEN	Kenya	1	PERCENT	Percentage	2013	75	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	37.86096816	0.534797278	KEN	Kenya	1	PERCENT	Percentage	2014	81	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	37.86096816	0.534797278	KEN	Kenya	1	PERCENT	Percentage	2015	75	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	37.86096816	0.534797278	KEN	Kenya	1	PERCENT	Percentage	2016	78	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	408	127.1803633	40.1462645	PRK	Democratic People's Republic of Korea	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	408	127.1803633	40.1462645	PRK	Democratic People's Republic of Korea	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	408	127.1803633	40.1462645	PRK	Democratic People's Republic of Korea	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	408	127.1803633	40.1462645	PRK	Democratic People's Republic of Korea	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	408	127.1803633	40.1462645	PRK	Democratic People's Republic of Korea	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	408	127.1803633	40.1462645	PRK	Democratic People's Republic of Korea	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	408	127.1803633	40.1462645	PRK	Democratic People's Republic of Korea	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	408	127.1803633	40.1462645	PRK	Democratic People's Republic of Korea	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	408	127.1803633	40.1462645	PRK	Democratic People's Republic of Korea	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	127.8610254	36.45201023	KOR	Republic of Korea	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	127.8610254	36.45201023	KOR	Republic of Korea	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	127.8610254	36.45201023	KOR	Republic of Korea	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	127.8610254	36.45201023	KOR	Republic of Korea	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	127.8610254	36.45201023	KOR	Republic of Korea	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	127.8610254	36.45201023	KOR	Republic of Korea	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	127.8610254	36.45201023	KOR	Republic of Korea	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	127.8610254	36.45201023	KOR	Republic of Korea	1	PERCENT	Percentage	2015	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	127.8610254	36.45201023	KOR	Republic of Korea	1	PERCENT	Percentage	2016	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	47.49305029	29.53949468	KWT	Kuwait	1	PERCENT	Percentage	2008	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	47.49305029	29.53949468	KWT	Kuwait	1	PERCENT	Percentage	2009	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	47.49305029	29.53949468	KWT	Kuwait	1	PERCENT	Percentage	2010	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	47.49305029	29.53949468	KWT	Kuwait	1	PERCENT	Percentage	2011	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	47.49305029	29.53949468	KWT	Kuwait	1	PERCENT	Percentage	2012	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	47.49305029	29.53949468	KWT	Kuwait	1	PERCENT	Percentage	2013	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	47.49305029	29.53949468	KWT	Kuwait	1	PERCENT	Percentage	2014	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	47.49305029	29.53949468	KWT	Kuwait	1	PERCENT	Percentage	2015	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	47.49305029	29.53949468	KWT	Kuwait	1	PERCENT	Percentage	2016	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	417	74.52324839	41.46204516	KGZ	Kyrgyzstan	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	417	74.52324839	41.46204516	KGZ	Kyrgyzstan	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	417	74.52324839	41.46204516	KGZ	Kyrgyzstan	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	417	74.52324839	41.46204516	KGZ	Kyrgyzstan	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	417	74.52324839	41.46204516	KGZ	Kyrgyzstan	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	417	74.52324839	41.46204516	KGZ	Kyrgyzstan	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	417	74.52324839	41.46204516	KGZ	Kyrgyzstan	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	417	74.52324839	41.46204516	KGZ	Kyrgyzstan	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	417	74.52324839	41.46204516	KGZ	Kyrgyzstan	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	101.9901968	20.27482773	LAO	Lao People's Democratic Republic	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	101.9901968	20.27482773	LAO	Lao People's Democratic Republic	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	101.9901968	20.27482773	LAO	Lao People's Democratic Republic	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	101.9901968	20.27482773	LAO	Lao People's Democratic Republic	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	101.9901968	20.27482773	LAO	Lao People's Democratic Republic	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	101.9901968	20.27482773	LAO	Lao People's Democratic Republic	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	101.9901968	20.27482773	LAO	Lao People's Democratic Republic	1	PERCENT	Percentage	2014	72	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	101.9901968	20.27482773	LAO	Lao People's Democratic Republic	1	PERCENT	Percentage	2015	77	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	101.9901968	20.27482773	LAO	Lao People's Democratic Republic	1	PERCENT	Percentage	2016	78	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	422	35.89391711	33.92152458	LBN	Lebanon	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	422	35.89391711	33.92152458	LBN	Lebanon	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	422	35.89391711	33.92152458	LBN	Lebanon	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	422	35.89391711	33.92152458	LBN	Lebanon	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	422	35.89391711	33.92152458	LBN	Lebanon	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	422	35.89391711	33.92152458	LBN	Lebanon	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	422	35.89391711	33.92152458	LBN	Lebanon	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	422	35.89391711	33.92152458	LBN	Lebanon	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	422	35.89391711	33.92152458	LBN	Lebanon	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	28.25362195	-29.58041814	LSO	Lesotho	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	28.25362195	-29.58041814	LSO	Lesotho	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	28.25362195	-29.58041814	LSO	Lesotho	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	28.25362195	-29.58041814	LSO	Lesotho	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	28.25362195	-29.58041814	LSO	Lesotho	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	28.25362195	-29.58041814	LSO	Lesotho	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	28.25362195	-29.58041814	LSO	Lesotho	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	28.25362195	-29.58041814	LSO	Lesotho	1	PERCENT	Percentage	2015	29	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	28.25362195	-29.58041814	LSO	Lesotho	1	PERCENT	Percentage	2016	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	26.42461876	56.64196636	LVA	Latvia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	26.42461876	56.64196636	LVA	Latvia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	26.42461876	56.64196636	LVA	Latvia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	26.42461876	56.64196636	LVA	Latvia	1	PERCENT	Percentage	2011	76	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	26.42461876	56.64196636	LVA	Latvia	1	PERCENT	Percentage	2012	55	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	26.42461876	56.64196636	LVA	Latvia	1	PERCENT	Percentage	2013	83	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	26.42461876	56.64196636	LVA	Latvia	1	PERCENT	Percentage	2014	83	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	26.42461876	56.64196636	LVA	Latvia	1	PERCENT	Percentage	2015	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	26.42461876	56.64196636	LVA	Latvia	1	PERCENT	Percentage	2016	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	-9.311879038	6.448381009	LBR	Liberia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	-9.311879038	6.448381009	LBR	Liberia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	-9.311879038	6.448381009	LBR	Liberia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	-9.311879038	6.448381009	LBR	Liberia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	-9.311879038	6.448381009	LBR	Liberia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	-9.311879038	6.448381009	LBR	Liberia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	-9.311879038	6.448381009	LBR	Liberia	1	PERCENT	Percentage	2014	45	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	-9.311879038	6.448381009	LBR	Liberia	1	PERCENT	Percentage	2015	56	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	-9.311879038	6.448381009	LBR	Liberia	1	PERCENT	Percentage	2016	79	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	18.0295985	27.04042819	LBY	Libya	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	18.0295985	27.04042819	LBY	Libya	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	18.0295985	27.04042819	LBY	Libya	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	18.0295985	27.04042819	LBY	Libya	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	18.0295985	27.04042819	LBY	Libya	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	18.0295985	27.04042819	LBY	Libya	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	18.0295985	27.04042819	LBY	Libya	1	PERCENT	Percentage	2014	39	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	18.0295985	27.04042819	LBY	Libya	1	PERCENT	Percentage	2015	71	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	18.0295985	27.04042819	LBY	Libya	1	PERCENT	Percentage	2016	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	438	9.552985019	47.14167005	LIE	Liechtenstein	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	438	9.552985019	47.14167005	LIE	Liechtenstein	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	438	9.552985019	47.14167005	LIE	Liechtenstein	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	438	9.552985019	47.14167005	LIE	Liechtenstein	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	438	9.552985019	47.14167005	LIE	Liechtenstein	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	438	9.552985019	47.14167005	LIE	Liechtenstein	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	438	9.552985019	47.14167005	LIE	Liechtenstein	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	438	9.552985019	47.14167005	LIE	Liechtenstein	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	438	9.552985019	47.14167005	LIE	Liechtenstein	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	440	23.90517807	55.33680309	LTU	Lithuania	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	440	23.90517807	55.33680309	LTU	Lithuania	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	440	23.90517807	55.33680309	LTU	Lithuania	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	440	23.90517807	55.33680309	LTU	Lithuania	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	440	23.90517807	55.33680309	LTU	Lithuania	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	440	23.90517807	55.33680309	LTU	Lithuania	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	440	23.90517807	55.33680309	LTU	Lithuania	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	440	23.90517807	55.33680309	LTU	Lithuania	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	440	23.90517807	55.33680309	LTU	Lithuania	1	PERCENT	Percentage	2016	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	6.092656563	49.77679538	LUX	Luxembourg	1	PERCENT	Percentage	2008	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	6.092656563	49.77679538	LUX	Luxembourg	1	PERCENT	Percentage	2009	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	6.092656563	49.77679538	LUX	Luxembourg	1	PERCENT	Percentage	2010	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	6.092656563	49.77679538	LUX	Luxembourg	1	PERCENT	Percentage	2011	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	6.092656563	49.77679538	LUX	Luxembourg	1	PERCENT	Percentage	2012	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	6.092656563	49.77679538	LUX	Luxembourg	1	PERCENT	Percentage	2013	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	6.092656563	49.77679538	LUX	Luxembourg	1	PERCENT	Percentage	2014	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	6.092656563	49.77679538	LUX	Luxembourg	1	PERCENT	Percentage	2015	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	6.092656563	49.77679538	LUX	Luxembourg	1	PERCENT	Percentage	2016	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	446	113.5665388	22.1237259	MAC	China, Macao Special Administrative Region	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	446	113.5665388	22.1237259	MAC	China, Macao Special Administrative Region	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	446	113.5665388	22.1237259	MAC	China, Macao Special Administrative Region	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	446	113.5665388	22.1237259	MAC	China, Macao Special Administrative Region	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	446	113.5665388	22.1237259	MAC	China, Macao Special Administrative Region	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	446	113.5665388	22.1237259	MAC	China, Macao Special Administrative Region	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	446	113.5665388	22.1237259	MAC	China, Macao Special Administrative Region	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	446	113.5665388	22.1237259	MAC	China, Macao Special Administrative Region	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	446	113.5665388	22.1237259	MAC	China, Macao Special Administrative Region	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	46.6982339	-19.38514785	MDG	Madagascar	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	46.6982339	-19.38514785	MDG	Madagascar	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	46.6982339	-19.38514785	MDG	Madagascar	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	46.6982339	-19.38514785	MDG	Madagascar	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	46.6982339	-19.38514785	MDG	Madagascar	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	46.6982339	-19.38514785	MDG	Madagascar	1	PERCENT	Percentage	2013	76	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	46.6982339	-19.38514785	MDG	Madagascar	1	PERCENT	Percentage	2014	72	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	46.6982339	-19.38514785	MDG	Madagascar	1	PERCENT	Percentage	2015	69	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	46.6982339	-19.38514785	MDG	Madagascar	1	PERCENT	Percentage	2016	76	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	33.4884625	-13.40819859	MWI	Malawi	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	33.4884625	-13.40819859	MWI	Malawi	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	33.4884625	-13.40819859	MWI	Malawi	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	33.4884625	-13.40819859	MWI	Malawi	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	33.4884625	-13.40819859	MWI	Malawi	1	PERCENT	Percentage	2012	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	33.4884625	-13.40819859	MWI	Malawi	1	PERCENT	Percentage	2013	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	33.4884625	-13.40819859	MWI	Malawi	1	PERCENT	Percentage	2014	87	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	33.4884625	-13.40819859	MWI	Malawi	1	PERCENT	Percentage	2015	88	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	33.4884625	-13.40819859	MWI	Malawi	1	PERCENT	Percentage	2016	83	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	458	116.8346314	5.452415309	MYS	Malaysia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	458	116.8346314	5.452415309	MYS	Malaysia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	458	116.8346314	5.452415309	MYS	Malaysia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	458	116.8346314	5.452415309	MYS	Malaysia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	458	116.8346314	5.452415309	MYS	Malaysia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	458	116.8346314	5.452415309	MYS	Malaysia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	458	116.8346314	5.452415309	MYS	Malaysia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	458	116.8346314	5.452415309	MYS	Malaysia	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	458	116.8346314	5.452415309	MYS	Malaysia	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	462	73.09672546	-0.614385021	MDV	Maldives	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	462	73.09672546	-0.614385021	MDV	Maldives	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	462	73.09672546	-0.614385021	MDV	Maldives	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	462	73.09672546	-0.614385021	MDV	Maldives	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	462	73.09672546	-0.614385021	MDV	Maldives	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	462	73.09672546	-0.614385021	MDV	Maldives	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	462	73.09672546	-0.614385021	MDV	Maldives	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	462	73.09672546	-0.614385021	MDV	Maldives	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	462	73.09672546	-0.614385021	MDV	Maldives	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	-3.522016039	17.35311254	MLI	Mali	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	-3.522016039	17.35311254	MLI	Mali	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	-3.522016039	17.35311254	MLI	Mali	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	-3.522016039	17.35311254	MLI	Mali	1	PERCENT	Percentage	2011	56	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	-3.522016039	17.35311254	MLI	Mali	1	PERCENT	Percentage	2012	68	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	-3.522016039	17.35311254	MLI	Mali	1	PERCENT	Percentage	2013	71	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	-3.522016039	17.35311254	MLI	Mali	1	PERCENT	Percentage	2014	73	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	-3.522016039	17.35311254	MLI	Mali	1	PERCENT	Percentage	2015	53	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	-3.522016039	17.35311254	MLI	Mali	1	PERCENT	Percentage	2016	70	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	470	14.44617519	35.89194275	MLT	Malta	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	470	14.44617519	35.89194275	MLT	Malta	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	470	14.44617519	35.89194275	MLT	Malta	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	470	14.44617519	35.89194275	MLT	Malta	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	470	14.44617519	35.89194275	MLT	Malta	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	470	14.44617519	35.89194275	MLT	Malta	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	470	14.44617519	35.89194275	MLT	Malta	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	470	14.44617519	35.89194275	MLT	Malta	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	470	14.44617519	35.89194275	MLT	Malta	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	474	-60.91544135	14.56086108	MTQ	Martinique	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	474	-60.91544135	14.56086108	MTQ	Martinique	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	474	-60.91544135	14.56086108	MTQ	Martinique	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	474	-60.91544135	14.56086108	MTQ	Martinique	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	474	-60.91544135	14.56086108	MTQ	Martinique	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	474	-60.91544135	14.56086108	MTQ	Martinique	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	474	-60.91544135	14.56086108	MTQ	Martinique	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	474	-60.91544135	14.56086108	MTQ	Martinique	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	474	-60.91544135	14.56086108	MTQ	Martinique	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	-10.33187259	20.26089546	MRT	Mauritania	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	-10.33187259	20.26089546	MRT	Mauritania	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	-10.33187259	20.26089546	MRT	Mauritania	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	-10.33187259	20.26089546	MRT	Mauritania	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	-10.33187259	20.26089546	MRT	Mauritania	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	-10.33187259	20.26089546	MRT	Mauritania	1	PERCENT	Percentage	2013	1	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	-10.33187259	20.26089546	MRT	Mauritania	1	PERCENT	Percentage	2014	71	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	-10.33187259	20.26089546	MRT	Mauritania	1	PERCENT	Percentage	2015	71	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	-10.33187259	20.26089546	MRT	Mauritania	1	PERCENT	Percentage	2016	73	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	480	57.568022	-20.28581998	MUS	Mauritius	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	480	57.568022	-20.28581998	MUS	Mauritius	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	480	57.568022	-20.28581998	MUS	Mauritius	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	480	57.568022	-20.28581998	MUS	Mauritius	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	480	57.568022	-20.28581998	MUS	Mauritius	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	480	57.568022	-20.28581998	MUS	Mauritius	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	480	57.568022	-20.28581998	MUS	Mauritius	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	480	57.568022	-20.28581998	MUS	Mauritius	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	480	57.568022	-20.28581998	MUS	Mauritius	1	PERCENT	Percentage	2016	10	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	-102.5148166	23.93378032	MEX	Mexico	1	PERCENT	Percentage	2008	14	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	-102.5148166	23.93378032	MEX	Mexico	1	PERCENT	Percentage	2009	46	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	-102.5148166	23.93378032	MEX	Mexico	1	PERCENT	Percentage	2010	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	-102.5148166	23.93378032	MEX	Mexico	1	PERCENT	Percentage	2011	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	-102.5148166	23.93378032	MEX	Mexico	1	PERCENT	Percentage	2012	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	-102.5148166	23.93378032	MEX	Mexico	1	PERCENT	Percentage	2013	84	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	-102.5148166	23.93378032	MEX	Mexico	1	PERCENT	Percentage	2014	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	-102.5148166	23.93378032	MEX	Mexico	1	PERCENT	Percentage	2015	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	-102.5148166	23.93378032	MEX	Mexico	1	PERCENT	Percentage	2016	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	492	7.424214814	43.73532918	MCO	Monaco	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	492	7.424214814	43.73532918	MCO	Monaco	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	492	7.424214814	43.73532918	MCO	Monaco	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	492	7.424214814	43.73532918	MCO	Monaco	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	492	7.424214814	43.73532918	MCO	Monaco	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	492	7.424214814	43.73532918	MCO	Monaco	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	492	7.424214814	43.73532918	MCO	Monaco	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	492	7.424214814	43.73532918	MCO	Monaco	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	492	7.424214814	43.73532918	MCO	Monaco	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	496	103.0728057	46.83892054	MNG	Mongolia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	496	103.0728057	46.83892054	MNG	Mongolia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	496	103.0728057	46.83892054	MNG	Mongolia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	496	103.0728057	46.83892054	MNG	Mongolia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	496	103.0728057	46.83892054	MNG	Mongolia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	496	103.0728057	46.83892054	MNG	Mongolia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	496	103.0728057	46.83892054	MNG	Mongolia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	496	103.0728057	46.83892054	MNG	Mongolia	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	496	103.0728057	46.83892054	MNG	Mongolia	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	28.4650624	47.20236795	MDA	Republic of Moldova	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	28.4650624	47.20236795	MDA	Republic of Moldova	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	28.4650624	47.20236795	MDA	Republic of Moldova	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	28.4650624	47.20236795	MDA	Republic of Moldova	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	28.4650624	47.20236795	MDA	Republic of Moldova	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	28.4650624	47.20236795	MDA	Republic of Moldova	1	PERCENT	Percentage	2013	1	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	28.4650624	47.20236795	MDA	Republic of Moldova	1	PERCENT	Percentage	2014	28	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	28.4650624	47.20236795	MDA	Republic of Moldova	1	PERCENT	Percentage	2015	71	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	28.4650624	47.20236795	MDA	Republic of Moldova	1	PERCENT	Percentage	2016	77	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	499	19.25214024	42.78717043	MNE	Montenegro	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	499	19.25214024	42.78717043	MNE	Montenegro	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	499	19.25214024	42.78717043	MNE	Montenegro	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	499	19.25214024	42.78717043	MNE	Montenegro	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	499	19.25214024	42.78717043	MNE	Montenegro	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	499	19.25214024	42.78717043	MNE	Montenegro	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	499	19.25214024	42.78717043	MNE	Montenegro	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	499	19.25214024	42.78717043	MNE	Montenegro	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	499	19.25214024	42.78717043	MNE	Montenegro	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	500	-62.19261223	16.73558313	MSR	Montserrat	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	500	-62.19261223	16.73558313	MSR	Montserrat	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	500	-62.19261223	16.73558313	MSR	Montserrat	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	500	-62.19261223	16.73558313	MSR	Montserrat	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	500	-62.19261223	16.73558313	MSR	Montserrat	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	500	-62.19261223	16.73558313	MSR	Montserrat	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	500	-62.19261223	16.73558313	MSR	Montserrat	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	500	-62.19261223	16.73558313	MSR	Montserrat	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	500	-62.19261223	16.73558313	MSR	Montserrat	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	-6.281942841	31.8440131	MAR	Morocco	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	-6.281942841	31.8440131	MAR	Morocco	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	-6.281942841	31.8440131	MAR	Morocco	1	PERCENT	Percentage	2010	1	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	-6.281942841	31.8440131	MAR	Morocco	1	PERCENT	Percentage	2011	23	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	-6.281942841	31.8440131	MAR	Morocco	1	PERCENT	Percentage	2012	72	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	-6.281942841	31.8440131	MAR	Morocco	1	PERCENT	Percentage	2013	80	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	-6.281942841	31.8440131	MAR	Morocco	1	PERCENT	Percentage	2014	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	-6.281942841	31.8440131	MAR	Morocco	1	PERCENT	Percentage	2015	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	-6.281942841	31.8440131	MAR	Morocco	1	PERCENT	Percentage	2016	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	38.18479941	-14.27963886	MOZ	Mozambique	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	38.18479941	-14.27963886	MOZ	Mozambique	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	38.18479941	-14.27963886	MOZ	Mozambique	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	38.18479941	-14.27963886	MOZ	Mozambique	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	38.18479941	-14.27963886	MOZ	Mozambique	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	38.18479941	-14.27963886	MOZ	Mozambique	1	PERCENT	Percentage	2013	45	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	38.18479941	-14.27963886	MOZ	Mozambique	1	PERCENT	Percentage	2014	73	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	38.18479941	-14.27963886	MOZ	Mozambique	1	PERCENT	Percentage	2015	80	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	38.18479941	-14.27963886	MOZ	Mozambique	1	PERCENT	Percentage	2016	80	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	57.87743482	21.98805614	OMN	Oman	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	57.87743482	21.98805614	OMN	Oman	1	PERCENT	Percentage	2009	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	57.87743482	21.98805614	OMN	Oman	1	PERCENT	Percentage	2010	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	57.87743482	21.98805614	OMN	Oman	1	PERCENT	Percentage	2011	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	57.87743482	21.98805614	OMN	Oman	1	PERCENT	Percentage	2012	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	57.87743482	21.98805614	OMN	Oman	1	PERCENT	Percentage	2013	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	57.87743482	21.98805614	OMN	Oman	1	PERCENT	Percentage	2014	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	57.87743482	21.98805614	OMN	Oman	1	PERCENT	Percentage	2015	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	57.87743482	21.98805614	OMN	Oman	1	PERCENT	Percentage	2016	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	17.21907885	-22.13817068	NAM	Namibia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	17.21907885	-22.13817068	NAM	Namibia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	17.21907885	-22.13817068	NAM	Namibia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	17.21907885	-22.13817068	NAM	Namibia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	17.21907885	-22.13817068	NAM	Namibia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	17.21907885	-22.13817068	NAM	Namibia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	17.21907885	-22.13817068	NAM	Namibia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	17.21907885	-22.13817068	NAM	Namibia	1	PERCENT	Percentage	2015	81	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	17.21907885	-22.13817068	NAM	Namibia	1	PERCENT	Percentage	2016	81	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	520	166.92313	-0.528742623	NRU	Nauru	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	520	166.92313	-0.528742623	NRU	Nauru	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	520	166.92313	-0.528742623	NRU	Nauru	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	520	166.92313	-0.528742623	NRU	Nauru	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	520	166.92313	-0.528742623	NRU	Nauru	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	520	166.92313	-0.528742623	NRU	Nauru	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	520	166.92313	-0.528742623	NRU	Nauru	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	520	166.92313	-0.528742623	NRU	Nauru	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	520	166.92313	-0.528742623	NRU	Nauru	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	83.94678863	28.25866332	NPL	Nepal	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	83.94678863	28.25866332	NPL	Nepal	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	83.94678863	28.25866332	NPL	Nepal	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	83.94678863	28.25866332	NPL	Nepal	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	83.94678863	28.25866332	NPL	Nepal	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	83.94678863	28.25866332	NPL	Nepal	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	83.94678863	28.25866332	NPL	Nepal	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	83.94678863	28.25866332	NPL	Nepal	1	PERCENT	Percentage	2015	5	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	83.94678863	28.25866332	NPL	Nepal	1	PERCENT	Percentage	2016	46	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	5.331480568	51.86728884	NLD	Netherlands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	5.331480568	51.86728884	NLD	Netherlands	1	PERCENT	Percentage	2009	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	5.331480568	51.86728884	NLD	Netherlands	1	PERCENT	Percentage	2010	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	5.331480568	51.86728884	NLD	Netherlands	1	PERCENT	Percentage	2011	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	5.331480568	51.86728884	NLD	Netherlands	1	PERCENT	Percentage	2012	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	5.331480568	51.86728884	NLD	Netherlands	1	PERCENT	Percentage	2013	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	5.331480568	51.86728884	NLD	Netherlands	1	PERCENT	Percentage	2014	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	5.331480568	51.86728884	NLD	Netherlands	1	PERCENT	Percentage	2015	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	5.331480568	51.86728884	NLD	Netherlands	1	PERCENT	Percentage	2016	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	530	-68.30676179	12.22720635	ANT	Netherlands Antilles	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	530	-68.30676179	12.22720635	ANT	Netherlands Antilles	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	530	-68.30676179	12.22720635	ANT	Netherlands Antilles	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	530	-68.30676179	12.22720635	ANT	Netherlands Antilles	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	530	-68.30676179	12.22720635	ANT	Netherlands Antilles	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	530	-68.30676179	12.22720635	ANT	Netherlands Antilles	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	530	-68.30676179	12.22720635	ANT	Netherlands Antilles	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	530	-68.30676179	12.22720635	ANT	Netherlands Antilles	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	530	-68.30676179	12.22720635	ANT	Netherlands Antilles	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	531	-68.95033464	12.15058042	CUW	Curaçao	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	531	-68.95033464	12.15058042	CUW	Curaçao	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	531	-68.95033464	12.15058042	CUW	Curaçao	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	531	-68.95033464	12.15058042	CUW	Curaçao	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	531	-68.95033464	12.15058042	CUW	Curaçao	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	531	-68.95033464	12.15058042	CUW	Curaçao	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	531	-68.95033464	12.15058042	CUW	Curaçao	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	531	-68.95033464	12.15058042	CUW	Curaçao	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	531	-68.95033464	12.15058042	CUW	Curaçao	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	533	-69.97050586	12.50878756	ABW	Aruba	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	533	-69.97050586	12.50878756	ABW	Aruba	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	533	-69.97050586	12.50878756	ABW	Aruba	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	533	-69.97050586	12.50878756	ABW	Aruba	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	533	-69.97050586	12.50878756	ABW	Aruba	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	533	-69.97050586	12.50878756	ABW	Aruba	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	533	-69.97050586	12.50878756	ABW	Aruba	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	533	-69.97050586	12.50878756	ABW	Aruba	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	533	-69.97050586	12.50878756	ABW	Aruba	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	534	-63.06198692	18.03926508	SXM	Sint Maarten (Dutch part)	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	534	-63.06198692	18.03926508	SXM	Sint Maarten (Dutch part)	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	534	-63.06198692	18.03926508	SXM	Sint Maarten (Dutch part)	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	534	-63.06198692	18.03926508	SXM	Sint Maarten (Dutch part)	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	534	-63.06198692	18.03926508	SXM	Sint Maarten (Dutch part)	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	534	-63.06198692	18.03926508	SXM	Sint Maarten (Dutch part)	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	534	-63.06198692	18.03926508	SXM	Sint Maarten (Dutch part)	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	534	-63.06198692	18.03926508	SXM	Sint Maarten (Dutch part)	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	534	-63.06198692	18.03926508	SXM	Sint Maarten (Dutch part)	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	540	165.5067368	-21.41742531	NCL	New Caledonia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	540	165.5067368	-21.41742531	NCL	New Caledonia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	540	165.5067368	-21.41742531	NCL	New Caledonia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	540	165.5067368	-21.41742531	NCL	New Caledonia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	540	165.5067368	-21.41742531	NCL	New Caledonia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	540	165.5067368	-21.41742531	NCL	New Caledonia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	540	165.5067368	-21.41742531	NCL	New Caledonia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	540	165.5067368	-21.41742531	NCL	New Caledonia	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	540	165.5067368	-21.41742531	NCL	New Caledonia	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	548	167.0679779	-15.34445547	VUT	Vanuatu	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	548	167.0679779	-15.34445547	VUT	Vanuatu	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	548	167.0679779	-15.34445547	VUT	Vanuatu	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	548	167.0679779	-15.34445547	VUT	Vanuatu	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	548	167.0679779	-15.34445547	VUT	Vanuatu	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	548	167.0679779	-15.34445547	VUT	Vanuatu	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	548	167.0679779	-15.34445547	VUT	Vanuatu	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	548	167.0679779	-15.34445547	VUT	Vanuatu	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	548	167.0679779	-15.34445547	VUT	Vanuatu	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	170.4755673	-43.98721568	NZL	New Zealand	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	170.4755673	-43.98721568	NZL	New Zealand	1	PERCENT	Percentage	2009	87	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	170.4755673	-43.98721568	NZL	New Zealand	1	PERCENT	Percentage	2010	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	170.4755673	-43.98721568	NZL	New Zealand	1	PERCENT	Percentage	2011	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	170.4755673	-43.98721568	NZL	New Zealand	1	PERCENT	Percentage	2012	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	170.4755673	-43.98721568	NZL	New Zealand	1	PERCENT	Percentage	2013	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	170.4755673	-43.98721568	NZL	New Zealand	1	PERCENT	Percentage	2014	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	170.4755673	-43.98721568	NZL	New Zealand	1	PERCENT	Percentage	2015	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	170.4755673	-43.98721568	NZL	New Zealand	1	PERCENT	Percentage	2016	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	-85.03060315	12.84210839	NIC	Nicaragua	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	-85.03060315	12.84210839	NIC	Nicaragua	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	-85.03060315	12.84210839	NIC	Nicaragua	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	-85.03060315	12.84210839	NIC	Nicaragua	1	PERCENT	Percentage	2011	61	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	-85.03060315	12.84210839	NIC	Nicaragua	1	PERCENT	Percentage	2012	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	-85.03060315	12.84210839	NIC	Nicaragua	1	PERCENT	Percentage	2013	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	-85.03060315	12.84210839	NIC	Nicaragua	1	PERCENT	Percentage	2014	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	-85.03060315	12.84210839	NIC	Nicaragua	1	PERCENT	Percentage	2015	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	-85.03060315	12.84210839	NIC	Nicaragua	1	PERCENT	Percentage	2016	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	9.400167877	17.42143036	NER	Niger	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	9.400167877	17.42143036	NER	Niger	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	9.400167877	17.42143036	NER	Niger	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	9.400167877	17.42143036	NER	Niger	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	9.400167877	17.42143036	NER	Niger	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	9.400167877	17.42143036	NER	Niger	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	9.400167877	17.42143036	NER	Niger	1	PERCENT	Percentage	2014	13	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	9.400167877	17.42143036	NER	Niger	1	PERCENT	Percentage	2015	49	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	9.400167877	17.42143036	NER	Niger	1	PERCENT	Percentage	2016	64	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	8.097363256	9.585789025	NGA	Nigeria	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	8.097363256	9.585789025	NGA	Nigeria	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	8.097363256	9.585789025	NGA	Nigeria	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	8.097363256	9.585789025	NGA	Nigeria	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	8.097363256	9.585789025	NGA	Nigeria	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	8.097363256	9.585789025	NGA	Nigeria	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	8.097363256	9.585789025	NGA	Nigeria	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	8.097363256	9.585789025	NGA	Nigeria	1	PERCENT	Percentage	2015	13	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	8.097363256	9.585789025	NGA	Nigeria	1	PERCENT	Percentage	2016	26	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	-169.8601693	-19.05000475	NIU	Niue	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	-169.8601693	-19.05000475	NIU	Niue	1	PERCENT	Percentage	2009	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	-169.8601693	-19.05000475	NIU	Niue	1	PERCENT	Percentage	2010	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	-169.8601693	-19.05000475	NIU	Niue	1	PERCENT	Percentage	2011	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	-169.8601693	-19.05000475	NIU	Niue	1	PERCENT	Percentage	2012	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	-169.8601693	-19.05000475	NIU	Niue	1	PERCENT	Percentage	2013	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	-169.8601693	-19.05000475	NIU	Niue	1	PERCENT	Percentage	2014	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	-169.8601693	-19.05000475	NIU	Niue	1	PERCENT	Percentage	2015	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	-169.8601693	-19.05000475	NIU	Niue	1	PERCENT	Percentage	2016	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	574	167.9515548	-29.03230018	NFK	Norfolk Island	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	574	167.9515548	-29.03230018	NFK	Norfolk Island	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	574	167.9515548	-29.03230018	NFK	Norfolk Island	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	574	167.9515548	-29.03230018	NFK	Norfolk Island	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	574	167.9515548	-29.03230018	NFK	Norfolk Island	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	574	167.9515548	-29.03230018	NFK	Norfolk Island	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	574	167.9515548	-29.03230018	NFK	Norfolk Island	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	574	167.9515548	-29.03230018	NFK	Norfolk Island	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	574	167.9515548	-29.03230018	NFK	Norfolk Island	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	11.47846389	61.34311134	NOR	Norway	1	PERCENT	Percentage	2008	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	11.47846389	61.34311134	NOR	Norway	1	PERCENT	Percentage	2009	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	11.47846389	61.34311134	NOR	Norway	1	PERCENT	Percentage	2010	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	11.47846389	61.34311134	NOR	Norway	1	PERCENT	Percentage	2011	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	11.47846389	61.34311134	NOR	Norway	1	PERCENT	Percentage	2012	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	11.47846389	61.34311134	NOR	Norway	1	PERCENT	Percentage	2013	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	11.47846389	61.34311134	NOR	Norway	1	PERCENT	Percentage	2014	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	11.47846389	61.34311134	NOR	Norway	1	PERCENT	Percentage	2015	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	11.47846389	61.34311134	NOR	Norway	1	PERCENT	Percentage	2016	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	580	145.7582114	15.19099517	MNP	Northern Mariana Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	580	145.7582114	15.19099517	MNP	Northern Mariana Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	580	145.7582114	15.19099517	MNP	Northern Mariana Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	580	145.7582114	15.19099517	MNP	Northern Mariana Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	580	145.7582114	15.19099517	MNP	Northern Mariana Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	580	145.7582114	15.19099517	MNP	Northern Mariana Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	580	145.7582114	15.19099517	MNP	Northern Mariana Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	580	145.7582114	15.19099517	MNP	Northern Mariana Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	580	145.7582114	15.19099517	MNP	Northern Mariana Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	581	-162.4343752	5.874443968	UMI	US Minor Outlying Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	581	-162.4343752	5.874443968	UMI	US Minor Outlying Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	581	-162.4343752	5.874443968	UMI	US Minor Outlying Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	581	-162.4343752	5.874443968	UMI	US Minor Outlying Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	581	-162.4343752	5.874443968	UMI	US Minor Outlying Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	581	-162.4343752	5.874443968	UMI	US Minor Outlying Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	581	-162.4343752	5.874443968	UMI	US Minor Outlying Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	581	-162.4343752	5.874443968	UMI	US Minor Outlying Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	581	-162.4343752	5.874443968	UMI	US Minor Outlying Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	158.225216	6.880670092	FSM	Micronesia, Federated States of	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	158.225216	6.880670092	FSM	Micronesia, Federated States of	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	158.225216	6.880670092	FSM	Micronesia, Federated States of	1	PERCENT	Percentage	2010	70	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	158.225216	6.880670092	FSM	Micronesia, Federated States of	1	PERCENT	Percentage	2011	63	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	158.225216	6.880670092	FSM	Micronesia, Federated States of	1	PERCENT	Percentage	2012	60	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	158.225216	6.880670092	FSM	Micronesia, Federated States of	1	PERCENT	Percentage	2013	61	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	158.225216	6.880670092	FSM	Micronesia, Federated States of	1	PERCENT	Percentage	2014	64	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	158.225216	6.880670092	FSM	Micronesia, Federated States of	1	PERCENT	Percentage	2015	67	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	158.225216	6.880670092	FSM	Micronesia, Federated States of	1	PERCENT	Percentage	2016	63	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	171.0839119	7.110213497	MHL	Marshall Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	171.0839119	7.110213497	MHL	Marshall Islands	1	PERCENT	Percentage	2009	49	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	171.0839119	7.110213497	MHL	Marshall Islands	1	PERCENT	Percentage	2010	24	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	171.0839119	7.110213497	MHL	Marshall Islands	1	PERCENT	Percentage	2011	35	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	171.0839119	7.110213497	MHL	Marshall Islands	1	PERCENT	Percentage	2012	46	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	171.0839119	7.110213497	MHL	Marshall Islands	1	PERCENT	Percentage	2013	38	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	171.0839119	7.110213497	MHL	Marshall Islands	1	PERCENT	Percentage	2014	29	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	171.0839119	7.110213497	MHL	Marshall Islands	1	PERCENT	Percentage	2015	75	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	171.0839119	7.110213497	MHL	Marshall Islands	1	PERCENT	Percentage	2016	51	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	134.5733878	7.502307591	PLW	Palau	1	PERCENT	Percentage	2008	7	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	134.5733878	7.502307591	PLW	Palau	1	PERCENT	Percentage	2009	18	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	134.5733878	7.502307591	PLW	Palau	1	PERCENT	Percentage	2010	45	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	134.5733878	7.502307591	PLW	Palau	1	PERCENT	Percentage	2011	61	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	134.5733878	7.502307591	PLW	Palau	1	PERCENT	Percentage	2012	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	134.5733878	7.502307591	PLW	Palau	1	PERCENT	Percentage	2013	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	134.5733878	7.502307591	PLW	Palau	1	PERCENT	Percentage	2014	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	134.5733878	7.502307591	PLW	Palau	1	PERCENT	Percentage	2015	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	134.5733878	7.502307591	PLW	Palau	1	PERCENT	Percentage	2016	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	68.80479684	29.36491634	PAK	Pakistan	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	68.80479684	29.36491634	PAK	Pakistan	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	68.80479684	29.36491634	PAK	Pakistan	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	68.80479684	29.36491634	PAK	Pakistan	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	68.80479684	29.36491634	PAK	Pakistan	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	68.80479684	29.36491634	PAK	Pakistan	1	PERCENT	Percentage	2013	66	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	68.80479684	29.36491634	PAK	Pakistan	1	PERCENT	Percentage	2014	72	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	68.80479684	29.36491634	PAK	Pakistan	1	PERCENT	Percentage	2015	72	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	68.80479684	29.36491634	PAK	Pakistan	1	PERCENT	Percentage	2016	72	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	-81.26616623	8.450965746	PAN	Panama	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	-81.26616623	8.450965746	PAN	Panama	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	-81.26616623	8.450965746	PAN	Panama	1	PERCENT	Percentage	2010	48	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	-81.26616623	8.450965746	PAN	Panama	1	PERCENT	Percentage	2011	55	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	-81.26616623	8.450965746	PAN	Panama	1	PERCENT	Percentage	2012	62	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	-81.26616623	8.450965746	PAN	Panama	1	PERCENT	Percentage	2013	68	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	-81.26616623	8.450965746	PAN	Panama	1	PERCENT	Percentage	2014	75	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	-81.26616623	8.450965746	PAN	Panama	1	PERCENT	Percentage	2015	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	-81.26616623	8.450965746	PAN	Panama	1	PERCENT	Percentage	2016	83	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	145.8587761	-6.756057077	PNG	Papua New Guinea	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	145.8587761	-6.756057077	PNG	Papua New Guinea	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	145.8587761	-6.756057077	PNG	Papua New Guinea	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	145.8587761	-6.756057077	PNG	Papua New Guinea	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	145.8587761	-6.756057077	PNG	Papua New Guinea	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	145.8587761	-6.756057077	PNG	Papua New Guinea	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	145.8587761	-6.756057077	PNG	Papua New Guinea	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	145.8587761	-6.756057077	PNG	Papua New Guinea	1	PERCENT	Percentage	2015	20	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	145.8587761	-6.756057077	PNG	Papua New Guinea	1	PERCENT	Percentage	2016	20	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	-60.54854225	-21.70216237	PRY	Paraguay	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	-60.54854225	-21.70216237	PRY	Paraguay	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	-60.54854225	-21.70216237	PRY	Paraguay	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	-60.54854225	-21.70216237	PRY	Paraguay	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	-60.54854225	-21.70216237	PRY	Paraguay	1	PERCENT	Percentage	2012	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	-60.54854225	-21.70216237	PRY	Paraguay	1	PERCENT	Percentage	2013	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	-60.54854225	-21.70216237	PRY	Paraguay	1	PERCENT	Percentage	2014	88	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	-60.54854225	-21.70216237	PRY	Paraguay	1	PERCENT	Percentage	2015	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	-60.54854225	-21.70216237	PRY	Paraguay	1	PERCENT	Percentage	2016	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	-71.82093277	-13.58939705	PER	Peru	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	-71.82093277	-13.58939705	PER	Peru	1	PERCENT	Percentage	2009	9	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	-71.82093277	-13.58939705	PER	Peru	1	PERCENT	Percentage	2010	83	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	-71.82093277	-13.58939705	PER	Peru	1	PERCENT	Percentage	2011	82	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	-71.82093277	-13.58939705	PER	Peru	1	PERCENT	Percentage	2012	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	-71.82093277	-13.58939705	PER	Peru	1	PERCENT	Percentage	2013	85	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	-71.82093277	-13.58939705	PER	Peru	1	PERCENT	Percentage	2014	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	-71.82093277	-13.58939705	PER	Peru	1	PERCENT	Percentage	2015	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	-71.82093277	-13.58939705	PER	Peru	1	PERCENT	Percentage	2016	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	120.8601418	14.16591706	PHL	Philippines	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	120.8601418	14.16591706	PHL	Philippines	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	120.8601418	14.16591706	PHL	Philippines	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	120.8601418	14.16591706	PHL	Philippines	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	120.8601418	14.16591706	PHL	Philippines	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	120.8601418	14.16591706	PHL	Philippines	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	120.8601418	14.16591706	PHL	Philippines	1	PERCENT	Percentage	2014	35	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	120.8601418	14.16591706	PHL	Philippines	1	PERCENT	Percentage	2015	17	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	120.8601418	14.16591706	PHL	Philippines	1	PERCENT	Percentage	2016	36	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	612	-128.3225873	-24.37538456	PCN	Pitcairn	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	612	-128.3225873	-24.37538456	PCN	Pitcairn	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	612	-128.3225873	-24.37538456	PCN	Pitcairn	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	612	-128.3225873	-24.37538456	PCN	Pitcairn	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	612	-128.3225873	-24.37538456	PCN	Pitcairn	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	612	-128.3225873	-24.37538456	PCN	Pitcairn	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	612	-128.3225873	-24.37538456	PCN	Pitcairn	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	612	-128.3225873	-24.37538456	PCN	Pitcairn	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	612	-128.3225873	-24.37538456	PCN	Pitcairn	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	616	19.40660158	52.1226733	POL	Poland	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	616	19.40660158	52.1226733	POL	Poland	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	616	19.40660158	52.1226733	POL	Poland	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	616	19.40660158	52.1226733	POL	Poland	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	616	19.40660158	52.1226733	POL	Poland	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	616	19.40660158	52.1226733	POL	Poland	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	616	19.40660158	52.1226733	POL	Poland	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	616	19.40660158	52.1226733	POL	Poland	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	616	19.40660158	52.1226733	POL	Poland	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	620	-7.961599811	39.68509315	PRT	Portugal	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	620	-7.961599811	39.68509315	PRT	Portugal	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	620	-7.961599811	39.68509315	PRT	Portugal	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	620	-7.961599811	39.68509315	PRT	Portugal	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	620	-7.961599811	39.68509315	PRT	Portugal	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	620	-7.961599811	39.68509315	PRT	Portugal	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	620	-7.961599811	39.68509315	PRT	Portugal	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	620	-7.961599811	39.68509315	PRT	Portugal	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	620	-7.961599811	39.68509315	PRT	Portugal	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	-14.40182514	12.11760394	GNB	Guinea-Bissau	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	-14.40182514	12.11760394	GNB	Guinea-Bissau	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	-14.40182514	12.11760394	GNB	Guinea-Bissau	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	-14.40182514	12.11760394	GNB	Guinea-Bissau	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	-14.40182514	12.11760394	GNB	Guinea-Bissau	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	-14.40182514	12.11760394	GNB	Guinea-Bissau	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	-14.40182514	12.11760394	GNB	Guinea-Bissau	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	-14.40182514	12.11760394	GNB	Guinea-Bissau	1	PERCENT	Percentage	2015	10	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	-14.40182514	12.11760394	GNB	Guinea-Bissau	1	PERCENT	Percentage	2016	80	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	626	125.9451052	-8.797497247	TLS	Timor-Leste	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	626	125.9451052	-8.797497247	TLS	Timor-Leste	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	626	125.9451052	-8.797497247	TLS	Timor-Leste	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	626	125.9451052	-8.797497247	TLS	Timor-Leste	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	626	125.9451052	-8.797497247	TLS	Timor-Leste	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	626	125.9451052	-8.797497247	TLS	Timor-Leste	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	626	125.9451052	-8.797497247	TLS	Timor-Leste	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	626	125.9451052	-8.797497247	TLS	Timor-Leste	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	626	125.9451052	-8.797497247	TLS	Timor-Leste	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	630	-66.47591017	18.22753799	PRI	Puerto Rico	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	630	-66.47591017	18.22753799	PRI	Puerto Rico	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	630	-66.47591017	18.22753799	PRI	Puerto Rico	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	630	-66.47591017	18.22753799	PRI	Puerto Rico	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	630	-66.47591017	18.22753799	PRI	Puerto Rico	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	630	-66.47591017	18.22753799	PRI	Puerto Rico	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	630	-66.47591017	18.22753799	PRI	Puerto Rico	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	630	-66.47591017	18.22753799	PRI	Puerto Rico	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	630	-66.47591017	18.22753799	PRI	Puerto Rico	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	51.19152467	25.28355379	QAT	Qatar	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	51.19152467	25.28355379	QAT	Qatar	1	PERCENT	Percentage	2009	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	51.19152467	25.28355379	QAT	Qatar	1	PERCENT	Percentage	2010	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	51.19152467	25.28355379	QAT	Qatar	1	PERCENT	Percentage	2011	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	51.19152467	25.28355379	QAT	Qatar	1	PERCENT	Percentage	2012	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	51.19152467	25.28355379	QAT	Qatar	1	PERCENT	Percentage	2013	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	51.19152467	25.28355379	QAT	Qatar	1	PERCENT	Percentage	2014	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	51.19152467	25.28355379	QAT	Qatar	1	PERCENT	Percentage	2015	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	51.19152467	25.28355379	QAT	Qatar	1	PERCENT	Percentage	2016	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	638	55.53171398	-21.13183266	REU	Réunion	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	638	55.53171398	-21.13183266	REU	Réunion	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	638	55.53171398	-21.13183266	REU	Réunion	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	638	55.53171398	-21.13183266	REU	Réunion	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	638	55.53171398	-21.13183266	REU	Réunion	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	638	55.53171398	-21.13183266	REU	Réunion	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	638	55.53171398	-21.13183266	REU	Réunion	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	638	55.53171398	-21.13183266	REU	Réunion	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	638	55.53171398	-21.13183266	REU	Réunion	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	642	24.98481009	45.83893563	ROU	Romania	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	642	24.98481009	45.83893563	ROU	Romania	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	642	24.98481009	45.83893563	ROU	Romania	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	642	24.98481009	45.83893563	ROU	Romania	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	642	24.98481009	45.83893563	ROU	Romania	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	642	24.98481009	45.83893563	ROU	Romania	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	642	24.98481009	45.83893563	ROU	Romania	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	642	24.98481009	45.83893563	ROU	Romania	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	642	24.98481009	45.83893563	ROU	Romania	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	643	99.01404926	61.61899849	RUS	Russian Federation	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	643	99.01404926	61.61899849	RUS	Russian Federation	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	643	99.01404926	61.61899849	RUS	Russian Federation	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	643	99.01404926	61.61899849	RUS	Russian Federation	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	643	99.01404926	61.61899849	RUS	Russian Federation	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	643	99.01404926	61.61899849	RUS	Russian Federation	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	643	99.01404926	61.61899849	RUS	Russian Federation	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	643	99.01404926	61.61899849	RUS	Russian Federation	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	643	99.01404926	61.61899849	RUS	Russian Federation	1	PERCENT	Percentage	2016	35	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	29.92310194	-1.999842114	RWA	Rwanda	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	29.92310194	-1.999842114	RWA	Rwanda	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	29.92310194	-1.999842114	RWA	Rwanda	1	PERCENT	Percentage	2010	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	29.92310194	-1.999842114	RWA	Rwanda	1	PERCENT	Percentage	2011	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	29.92310194	-1.999842114	RWA	Rwanda	1	PERCENT	Percentage	2012	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	29.92310194	-1.999842114	RWA	Rwanda	1	PERCENT	Percentage	2013	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	29.92310194	-1.999842114	RWA	Rwanda	1	PERCENT	Percentage	2014	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	29.92310194	-1.999842114	RWA	Rwanda	1	PERCENT	Percentage	2015	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	29.92310194	-1.999842114	RWA	Rwanda	1	PERCENT	Percentage	2016	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	652	-62.83173536	17.89513362	BLM	Saint Barthélemy	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	652	-62.83173536	17.89513362	BLM	Saint Barthélemy	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	652	-62.83173536	17.89513362	BLM	Saint Barthélemy	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	652	-62.83173536	17.89513362	BLM	Saint Barthélemy	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	652	-62.83173536	17.89513362	BLM	Saint Barthélemy	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	652	-62.83173536	17.89513362	BLM	Saint Barthélemy	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	652	-62.83173536	17.89513362	BLM	Saint Barthélemy	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	652	-62.83173536	17.89513362	BLM	Saint Barthélemy	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	652	-62.83173536	17.89513362	BLM	Saint Barthélemy	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	654	-5.705752501	-15.96503946	SHN	Saint Helena	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	654	-5.705752501	-15.96503946	SHN	Saint Helena	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	654	-5.705752501	-15.96503946	SHN	Saint Helena	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	654	-5.705752501	-15.96503946	SHN	Saint Helena	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	654	-5.705752501	-15.96503946	SHN	Saint Helena	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	654	-5.705752501	-15.96503946	SHN	Saint Helena	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	654	-5.705752501	-15.96503946	SHN	Saint Helena	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	654	-5.705752501	-15.96503946	SHN	Saint Helena	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	654	-5.705752501	-15.96503946	SHN	Saint Helena	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	659	-62.76628613	17.33994219	KNA	Saint Kitts and Nevis	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	659	-62.76628613	17.33994219	KNA	Saint Kitts and Nevis	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	659	-62.76628613	17.33994219	KNA	Saint Kitts and Nevis	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	659	-62.76628613	17.33994219	KNA	Saint Kitts and Nevis	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	659	-62.76628613	17.33994219	KNA	Saint Kitts and Nevis	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	659	-62.76628613	17.33994219	KNA	Saint Kitts and Nevis	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	659	-62.76628613	17.33994219	KNA	Saint Kitts and Nevis	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	659	-62.76628613	17.33994219	KNA	Saint Kitts and Nevis	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	659	-62.76628613	17.33994219	KNA	Saint Kitts and Nevis	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	660	-63.05651612	18.21525315	AIA	Anguilla	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	660	-63.05651612	18.21525315	AIA	Anguilla	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	660	-63.05651612	18.21525315	AIA	Anguilla	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	660	-63.05651612	18.21525315	AIA	Anguilla	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	660	-63.05651612	18.21525315	AIA	Anguilla	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	660	-63.05651612	18.21525315	AIA	Anguilla	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	660	-63.05651612	18.21525315	AIA	Anguilla	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	660	-63.05651612	18.21525315	AIA	Anguilla	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	660	-63.05651612	18.21525315	AIA	Anguilla	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	662	-60.96529553	13.89405601	LCA	Saint Lucia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	662	-60.96529553	13.89405601	LCA	Saint Lucia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	662	-60.96529553	13.89405601	LCA	Saint Lucia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	662	-60.96529553	13.89405601	LCA	Saint Lucia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	662	-60.96529553	13.89405601	LCA	Saint Lucia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	662	-60.96529553	13.89405601	LCA	Saint Lucia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	662	-60.96529553	13.89405601	LCA	Saint Lucia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	662	-60.96529553	13.89405601	LCA	Saint Lucia	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	662	-60.96529553	13.89405601	LCA	Saint Lucia	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	663	-63.04505461	18.0882685	MAF	Saint Martin (French Part)	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	663	-63.04505461	18.0882685	MAF	Saint Martin (French Part)	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	663	-63.04505461	18.0882685	MAF	Saint Martin (French Part)	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	663	-63.04505461	18.0882685	MAF	Saint Martin (French Part)	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	663	-63.04505461	18.0882685	MAF	Saint Martin (French Part)	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	663	-63.04505461	18.0882685	MAF	Saint Martin (French Part)	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	663	-63.04505461	18.0882685	MAF	Saint Martin (French Part)	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	663	-63.04505461	18.0882685	MAF	Saint Martin (French Part)	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	663	-63.04505461	18.0882685	MAF	Saint Martin (French Part)	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	666	-56.33682442	46.85812735	SPM	Saint Pierre and Miquelon	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	666	-56.33682442	46.85812735	SPM	Saint Pierre and Miquelon	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	666	-56.33682442	46.85812735	SPM	Saint Pierre and Miquelon	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	666	-56.33682442	46.85812735	SPM	Saint Pierre and Miquelon	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	666	-56.33682442	46.85812735	SPM	Saint Pierre and Miquelon	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	666	-56.33682442	46.85812735	SPM	Saint Pierre and Miquelon	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	666	-56.33682442	46.85812735	SPM	Saint Pierre and Miquelon	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	666	-56.33682442	46.85812735	SPM	Saint Pierre and Miquelon	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	666	-56.33682442	46.85812735	SPM	Saint Pierre and Miquelon	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	670	-61.19024321	13.24627968	VCT	Saint Vincent and the Grenadines	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	670	-61.19024321	13.24627968	VCT	Saint Vincent and the Grenadines	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	670	-61.19024321	13.24627968	VCT	Saint Vincent and the Grenadines	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	670	-61.19024321	13.24627968	VCT	Saint Vincent and the Grenadines	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	670	-61.19024321	13.24627968	VCT	Saint Vincent and the Grenadines	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	670	-61.19024321	13.24627968	VCT	Saint Vincent and the Grenadines	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	670	-61.19024321	13.24627968	VCT	Saint Vincent and the Grenadines	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	670	-61.19024321	13.24627968	VCT	Saint Vincent and the Grenadines	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	670	-61.19024321	13.24627968	VCT	Saint Vincent and the Grenadines	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	674	12.46329038	43.93841766	SMR	San Marino	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	674	12.46329038	43.93841766	SMR	San Marino	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	674	12.46329038	43.93841766	SMR	San Marino	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	674	12.46329038	43.93841766	SMR	San Marino	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	674	12.46329038	43.93841766	SMR	San Marino	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	674	12.46329038	43.93841766	SMR	San Marino	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	674	12.46329038	43.93841766	SMR	San Marino	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	674	12.46329038	43.93841766	SMR	San Marino	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	674	12.46329038	43.93841766	SMR	San Marino	1	PERCENT	Percentage	2016	12	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	6.609772265	0.241554875	STP	Sao Tome and Principe	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	6.609772265	0.241554875	STP	Sao Tome and Principe	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	6.609772265	0.241554875	STP	Sao Tome and Principe	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	6.609772265	0.241554875	STP	Sao Tome and Principe	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	6.609772265	0.241554875	STP	Sao Tome and Principe	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	6.609772265	0.241554875	STP	Sao Tome and Principe	1	PERCENT	Percentage	2013	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	6.609772265	0.241554875	STP	Sao Tome and Principe	1	PERCENT	Percentage	2014	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	6.609772265	0.241554875	STP	Sao Tome and Principe	1	PERCENT	Percentage	2015	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	6.609772265	0.241554875	STP	Sao Tome and Principe	1	PERCENT	Percentage	2016	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	44.54763347	24.12594211	SAU	Saudi Arabia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	44.54763347	24.12594211	SAU	Saudi Arabia	1	PERCENT	Percentage	2009	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	44.54763347	24.12594211	SAU	Saudi Arabia	1	PERCENT	Percentage	2010	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	44.54763347	24.12594211	SAU	Saudi Arabia	1	PERCENT	Percentage	2011	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	44.54763347	24.12594211	SAU	Saudi Arabia	1	PERCENT	Percentage	2012	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	44.54763347	24.12594211	SAU	Saudi Arabia	1	PERCENT	Percentage	2013	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	44.54763347	24.12594211	SAU	Saudi Arabia	1	PERCENT	Percentage	2014	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	44.54763347	24.12594211	SAU	Saudi Arabia	1	PERCENT	Percentage	2015	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	44.54763347	24.12594211	SAU	Saudi Arabia	1	PERCENT	Percentage	2016	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	-14.46636926	14.35920905	SEN	Senegal	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	-14.46636926	14.35920905	SEN	Senegal	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	-14.46636926	14.35920905	SEN	Senegal	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	-14.46636926	14.35920905	SEN	Senegal	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	-14.46636926	14.35920905	SEN	Senegal	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	-14.46636926	14.35920905	SEN	Senegal	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	-14.46636926	14.35920905	SEN	Senegal	1	PERCENT	Percentage	2014	81	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	-14.46636926	14.35920905	SEN	Senegal	1	PERCENT	Percentage	2015	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	-14.46636926	14.35920905	SEN	Senegal	1	PERCENT	Percentage	2016	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	688	20.805876	44.03145697	SRB	Serbia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	688	20.805876	44.03145697	SRB	Serbia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	688	20.805876	44.03145697	SRB	Serbia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	688	20.805876	44.03145697	SRB	Serbia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	688	20.805876	44.03145697	SRB	Serbia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	688	20.805876	44.03145697	SRB	Serbia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	688	20.805876	44.03145697	SRB	Serbia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	688	20.805876	44.03145697	SRB	Serbia	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	688	20.805876	44.03145697	SRB	Serbia	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	690	55.46561591	-4.678053059	SYC	Seychelles	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	690	55.46561591	-4.678053059	SYC	Seychelles	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	690	55.46561591	-4.678053059	SYC	Seychelles	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	690	55.46561591	-4.678053059	SYC	Seychelles	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	690	55.46561591	-4.678053059	SYC	Seychelles	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	690	55.46561591	-4.678053059	SYC	Seychelles	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	690	55.46561591	-4.678053059	SYC	Seychelles	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	690	55.46561591	-4.678053059	SYC	Seychelles	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	690	55.46561591	-4.678053059	SYC	Seychelles	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	-11.78306584	8.568604164	SLE	Sierra Leone	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	-11.78306584	8.568604164	SLE	Sierra Leone	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	-11.78306584	8.568604164	SLE	Sierra Leone	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	-11.78306584	8.568604164	SLE	Sierra Leone	1	PERCENT	Percentage	2011	75	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	-11.78306584	8.568604164	SLE	Sierra Leone	1	PERCENT	Percentage	2012	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	-11.78306584	8.568604164	SLE	Sierra Leone	1	PERCENT	Percentage	2013	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	-11.78306584	8.568604164	SLE	Sierra Leone	1	PERCENT	Percentage	2014	83	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	-11.78306584	8.568604164	SLE	Sierra Leone	1	PERCENT	Percentage	2015	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	-11.78306584	8.568604164	SLE	Sierra Leone	1	PERCENT	Percentage	2016	84	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	103.8107883	1.361009155	SGP	Singapore	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	103.8107883	1.361009155	SGP	Singapore	1	PERCENT	Percentage	2009	17	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	103.8107883	1.361009155	SGP	Singapore	1	PERCENT	Percentage	2010	22	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	103.8107883	1.361009155	SGP	Singapore	1	PERCENT	Percentage	2011	40	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	103.8107883	1.361009155	SGP	Singapore	1	PERCENT	Percentage	2012	52	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	103.8107883	1.361009155	SGP	Singapore	1	PERCENT	Percentage	2013	60	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	103.8107883	1.361009155	SGP	Singapore	1	PERCENT	Percentage	2014	69	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	103.8107883	1.361009155	SGP	Singapore	1	PERCENT	Percentage	2015	75	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	103.8107883	1.361009155	SGP	Singapore	1	PERCENT	Percentage	2016	78	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	19.48495604	48.70741446	SVK	Slovakia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	19.48495604	48.70741446	SVK	Slovakia	1	PERCENT	Percentage	2009	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	19.48495604	48.70741446	SVK	Slovakia	1	PERCENT	Percentage	2010	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	19.48495604	48.70741446	SVK	Slovakia	1	PERCENT	Percentage	2011	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	19.48495604	48.70741446	SVK	Slovakia	1	PERCENT	Percentage	2012	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	19.48495604	48.70741446	SVK	Slovakia	1	PERCENT	Percentage	2013	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	19.48495604	48.70741446	SVK	Slovakia	1	PERCENT	Percentage	2014	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	19.48495604	48.70741446	SVK	Slovakia	1	PERCENT	Percentage	2015	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	19.48495604	48.70741446	SVK	Slovakia	1	PERCENT	Percentage	2016	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	704	105.802499	10.09643079	VNM	Viet Nam	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	704	105.802499	10.09643079	VNM	Viet Nam	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	704	105.802499	10.09643079	VNM	Viet Nam	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	704	105.802499	10.09643079	VNM	Viet Nam	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	704	105.802499	10.09643079	VNM	Viet Nam	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	704	105.802499	10.09643079	VNM	Viet Nam	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	704	105.802499	10.09643079	VNM	Viet Nam	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	704	105.802499	10.09643079	VNM	Viet Nam	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	704	105.802499	10.09643079	VNM	Viet Nam	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	14.82209486	46.11958061	SVN	Slovenia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	14.82209486	46.11958061	SVN	Slovenia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	14.82209486	46.11958061	SVN	Slovenia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	14.82209486	46.11958061	SVN	Slovenia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	14.82209486	46.11958061	SVN	Slovenia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	14.82209486	46.11958061	SVN	Slovenia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	14.82209486	46.11958061	SVN	Slovenia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	14.82209486	46.11958061	SVN	Slovenia	1	PERCENT	Percentage	2015	49	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	14.82209486	46.11958061	SVN	Slovenia	1	PERCENT	Percentage	2016	50	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	706	46.20367477	4.406485729	SOM	Somalia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	706	46.20367477	4.406485729	SOM	Somalia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	706	46.20367477	4.406485729	SOM	Somalia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	706	46.20367477	4.406485729	SOM	Somalia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	706	46.20367477	4.406485729	SOM	Somalia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	706	46.20367477	4.406485729	SOM	Somalia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	706	46.20367477	4.406485729	SOM	Somalia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	706	46.20367477	4.406485729	SOM	Somalia	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	706	46.20367477	4.406485729	SOM	Somalia	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	24.67184355	-29.99957544	ZAF	South Africa	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	24.67184355	-29.99957544	ZAF	South Africa	1	PERCENT	Percentage	2009	10	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	24.67184355	-29.99957544	ZAF	South Africa	1	PERCENT	Percentage	2010	58	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	24.67184355	-29.99957544	ZAF	South Africa	1	PERCENT	Percentage	2011	62	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	24.67184355	-29.99957544	ZAF	South Africa	1	PERCENT	Percentage	2012	70	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	24.67184355	-29.99957544	ZAF	South Africa	1	PERCENT	Percentage	2013	69	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	24.67184355	-29.99957544	ZAF	South Africa	1	PERCENT	Percentage	2014	72	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	24.67184355	-29.99957544	ZAF	South Africa	1	PERCENT	Percentage	2015	77	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	24.67184355	-29.99957544	ZAF	South Africa	1	PERCENT	Percentage	2016	69	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	29.86909584	-19.00075492	ZWE	Zimbabwe	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	29.86909584	-19.00075492	ZWE	Zimbabwe	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	29.86909584	-19.00075492	ZWE	Zimbabwe	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	29.86909584	-19.00075492	ZWE	Zimbabwe	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	29.86909584	-19.00075492	ZWE	Zimbabwe	1	PERCENT	Percentage	2012	21	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	29.86909584	-19.00075492	ZWE	Zimbabwe	1	PERCENT	Percentage	2013	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	29.86909584	-19.00075492	ZWE	Zimbabwe	1	PERCENT	Percentage	2014	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	29.86909584	-19.00075492	ZWE	Zimbabwe	1	PERCENT	Percentage	2015	87	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	29.86909584	-19.00075492	ZWE	Zimbabwe	1	PERCENT	Percentage	2016	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	724	-3.554078296	40.39211472	ESP	Spain	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	724	-3.554078296	40.39211472	ESP	Spain	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	724	-3.554078296	40.39211472	ESP	Spain	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	724	-3.554078296	40.39211472	ESP	Spain	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	724	-3.554078296	40.39211472	ESP	Spain	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	724	-3.554078296	40.39211472	ESP	Spain	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	724	-3.554078296	40.39211472	ESP	Spain	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	724	-3.554078296	40.39211472	ESP	Spain	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	724	-3.554078296	40.39211472	ESP	Spain	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	728	30.32618773	7.290839152	SSD	South Sudan	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	728	30.32618773	7.290839152	SSD	South Sudan	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	728	30.32618773	7.290839152	SSD	South Sudan	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	728	30.32618773	7.290839152	SSD	South Sudan	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	728	30.32618773	7.290839152	SSD	South Sudan	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	728	30.32618773	7.290839152	SSD	South Sudan	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	728	30.32618773	7.290839152	SSD	South Sudan	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	728	30.32618773	7.290839152	SSD	South Sudan	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	728	30.32618773	7.290839152	SSD	South Sudan	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	732	-13.13515523	24.66265342	ESH	Western Sahara	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	732	-13.13515523	24.66265342	ESH	Western Sahara	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	732	-13.13515523	24.66265342	ESH	Western Sahara	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	732	-13.13515523	24.66265342	ESH	Western Sahara	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	732	-13.13515523	24.66265342	ESH	Western Sahara	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	732	-13.13515523	24.66265342	ESH	Western Sahara	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	732	-13.13515523	24.66265342	ESH	Western Sahara	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	732	-13.13515523	24.66265342	ESH	Western Sahara	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	732	-13.13515523	24.66265342	ESH	Western Sahara	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	736	29.95650159	16.02643066	SDN	Sudan	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	736	29.95650159	16.02643066	SDN	Sudan	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	736	29.95650159	16.02643066	SDN	Sudan	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	736	29.95650159	16.02643066	SDN	Sudan	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	736	29.95650159	16.02643066	SDN	Sudan	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	736	29.95650159	16.02643066	SDN	Sudan	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	736	29.95650159	16.02643066	SDN	Sudan	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	736	29.95650159	16.02643066	SDN	Sudan	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	736	29.95650159	16.02643066	SDN	Sudan	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	740	-55.90626394	4.132603197	SUR	Suriname	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	740	-55.90626394	4.132603197	SUR	Suriname	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	740	-55.90626394	4.132603197	SUR	Suriname	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	740	-55.90626394	4.132603197	SUR	Suriname	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	740	-55.90626394	4.132603197	SUR	Suriname	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	740	-55.90626394	4.132603197	SUR	Suriname	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	740	-55.90626394	4.132603197	SUR	Suriname	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	740	-55.90626394	4.132603197	SUR	Suriname	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	740	-55.90626394	4.132603197	SUR	Suriname	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	744	13.38071013	78.82894131	SJM	Svalbard and Jan Mayen Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	744	13.38071013	78.82894131	SJM	Svalbard and Jan Mayen Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	744	13.38071013	78.82894131	SJM	Svalbard and Jan Mayen Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	744	13.38071013	78.82894131	SJM	Svalbard and Jan Mayen Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	744	13.38071013	78.82894131	SJM	Svalbard and Jan Mayen Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	744	13.38071013	78.82894131	SJM	Svalbard and Jan Mayen Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	744	13.38071013	78.82894131	SJM	Svalbard and Jan Mayen Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	744	13.38071013	78.82894131	SJM	Svalbard and Jan Mayen Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	744	13.38071013	78.82894131	SJM	Svalbard and Jan Mayen Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	31.50149288	-26.56471011	SWZ	Swaziland	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	31.50149288	-26.56471011	SWZ	Swaziland	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	31.50149288	-26.56471011	SWZ	Swaziland	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	31.50149288	-26.56471011	SWZ	Swaziland	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	31.50149288	-26.56471011	SWZ	Swaziland	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	31.50149288	-26.56471011	SWZ	Swaziland	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	31.50149288	-26.56471011	SWZ	Swaziland	1	PERCENT	Percentage	2014	67	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	31.50149288	-26.56471011	SWZ	Swaziland	1	PERCENT	Percentage	2015	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	31.50149288	-26.56471011	SWZ	Swaziland	1	PERCENT	Percentage	2016	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	14.3775338	60.60103109	SWE	Sweden	1	PERCENT	Percentage	2008	60	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	14.3775338	60.60103109	SWE	Sweden	1	PERCENT	Percentage	2009	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	14.3775338	60.60103109	SWE	Sweden	1	PERCENT	Percentage	2010	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	14.3775338	60.60103109	SWE	Sweden	1	PERCENT	Percentage	2011	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	14.3775338	60.60103109	SWE	Sweden	1	PERCENT	Percentage	2012	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	14.3775338	60.60103109	SWE	Sweden	1	PERCENT	Percentage	2013	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	14.3775338	60.60103109	SWE	Sweden	1	PERCENT	Percentage	2014	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	14.3775338	60.60103109	SWE	Sweden	1	PERCENT	Percentage	2015	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	14.3775338	60.60103109	SWE	Sweden	1	PERCENT	Percentage	2016	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	8.223158	46.96617097	CHE	Switzerland	1	PERCENT	Percentage	2008	13	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	8.223158	46.96617097	CHE	Switzerland	1	PERCENT	Percentage	2009	25	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	8.223158	46.96617097	CHE	Switzerland	1	PERCENT	Percentage	2010	37	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	8.223158	46.96617097	CHE	Switzerland	1	PERCENT	Percentage	2011	50	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	8.223158	46.96617097	CHE	Switzerland	1	PERCENT	Percentage	2012	62	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	8.223158	46.96617097	CHE	Switzerland	1	PERCENT	Percentage	2013	75	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	8.223158	46.96617097	CHE	Switzerland	1	PERCENT	Percentage	2014	80	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	8.223158	46.96617097	CHE	Switzerland	1	PERCENT	Percentage	2015	81	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	8.223158	46.96617097	CHE	Switzerland	1	PERCENT	Percentage	2016	81	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	760	38.50466565	35.01676176	SYR	Syrian Arab Republic (Syria)	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	760	38.50466565	35.01676176	SYR	Syrian Arab Republic (Syria)	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	760	38.50466565	35.01676176	SYR	Syrian Arab Republic (Syria)	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	760	38.50466565	35.01676176	SYR	Syrian Arab Republic (Syria)	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	760	38.50466565	35.01676176	SYR	Syrian Arab Republic (Syria)	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	760	38.50466565	35.01676176	SYR	Syrian Arab Republic (Syria)	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	760	38.50466565	35.01676176	SYR	Syrian Arab Republic (Syria)	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	760	38.50466565	35.01676176	SYR	Syrian Arab Republic (Syria)	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	760	38.50466565	35.01676176	SYR	Syrian Arab Republic (Syria)	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	762	69.294998	38.43069666	TJK	Tajikistan	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	762	69.294998	38.43069666	TJK	Tajikistan	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	762	69.294998	38.43069666	TJK	Tajikistan	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	762	69.294998	38.43069666	TJK	Tajikistan	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	762	69.294998	38.43069666	TJK	Tajikistan	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	762	69.294998	38.43069666	TJK	Tajikistan	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	762	69.294998	38.43069666	TJK	Tajikistan	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	762	69.294998	38.43069666	TJK	Tajikistan	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	762	69.294998	38.43069666	TJK	Tajikistan	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	764	101.0202951	15.13089239	THA	Thailand	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	764	101.0202951	15.13089239	THA	Thailand	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	764	101.0202951	15.13089239	THA	Thailand	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	764	101.0202951	15.13089239	THA	Thailand	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	764	101.0202951	15.13089239	THA	Thailand	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	764	101.0202951	15.13089239	THA	Thailand	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	764	101.0202951	15.13089239	THA	Thailand	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	764	101.0202951	15.13089239	THA	Thailand	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	764	101.0202951	15.13089239	THA	Thailand	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	0.97835765	8.532096072	TGO	Togo	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	0.97835765	8.532096072	TGO	Togo	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	0.97835765	8.532096072	TGO	Togo	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	0.97835765	8.532096072	TGO	Togo	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	0.97835765	8.532096072	TGO	Togo	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	0.97835765	8.532096072	TGO	Togo	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	0.97835765	8.532096072	TGO	Togo	1	PERCENT	Percentage	2014	34	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	0.97835765	8.532096072	TGO	Togo	1	PERCENT	Percentage	2015	86	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	0.97835765	8.532096072	TGO	Togo	1	PERCENT	Percentage	2016	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	772	-171.8154473	-9.214545558	TKL	Tokelau	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	772	-171.8154473	-9.214545558	TKL	Tokelau	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	772	-171.8154473	-9.214545558	TKL	Tokelau	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	772	-171.8154473	-9.214545558	TKL	Tokelau	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	772	-171.8154473	-9.214545558	TKL	Tokelau	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	772	-171.8154473	-9.214545558	TKL	Tokelau	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	772	-171.8154473	-9.214545558	TKL	Tokelau	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	772	-171.8154473	-9.214545558	TKL	Tokelau	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	772	-171.8154473	-9.214545558	TKL	Tokelau	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	776	-175.1959991	-21.19511329	TON	Tonga	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	776	-175.1959991	-21.19511329	TON	Tonga	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	776	-175.1959991	-21.19511329	TON	Tonga	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	776	-175.1959991	-21.19511329	TON	Tonga	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	776	-175.1959991	-21.19511329	TON	Tonga	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	776	-175.1959991	-21.19511329	TON	Tonga	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	776	-175.1959991	-21.19511329	TON	Tonga	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	776	-175.1959991	-21.19511329	TON	Tonga	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	776	-175.1959991	-21.19511329	TON	Tonga	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	-61.29389504	10.41877263	TTO	Trinidad and Tobago	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	-61.29389504	10.41877263	TTO	Trinidad and Tobago	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	-61.29389504	10.41877263	TTO	Trinidad and Tobago	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	-61.29389504	10.41877263	TTO	Trinidad and Tobago	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	-61.29389504	10.41877263	TTO	Trinidad and Tobago	1	PERCENT	Percentage	2012	39	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	-61.29389504	10.41877263	TTO	Trinidad and Tobago	1	PERCENT	Percentage	2013	80	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	-61.29389504	10.41877263	TTO	Trinidad and Tobago	1	PERCENT	Percentage	2014	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	-61.29389504	10.41877263	TTO	Trinidad and Tobago	1	PERCENT	Percentage	2015	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	-61.29389504	10.41877263	TTO	Trinidad and Tobago	1	PERCENT	Percentage	2016	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	53.98279159	23.43322219	ARE	United Arab Emirates	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	53.98279159	23.43322219	ARE	United Arab Emirates	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	53.98279159	23.43322219	ARE	United Arab Emirates	1	PERCENT	Percentage	2010	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	53.98279159	23.43322219	ARE	United Arab Emirates	1	PERCENT	Percentage	2011	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	53.98279159	23.43322219	ARE	United Arab Emirates	1	PERCENT	Percentage	2012	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	53.98279159	23.43322219	ARE	United Arab Emirates	1	PERCENT	Percentage	2013	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	53.98279159	23.43322219	ARE	United Arab Emirates	1	PERCENT	Percentage	2014	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	53.98279159	23.43322219	ARE	United Arab Emirates	1	PERCENT	Percentage	2015	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	53.98279159	23.43322219	ARE	United Arab Emirates	1	PERCENT	Percentage	2016	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	788	9.572737411	34.11439971	TUN	Tunisia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	788	9.572737411	34.11439971	TUN	Tunisia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	788	9.572737411	34.11439971	TUN	Tunisia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	788	9.572737411	34.11439971	TUN	Tunisia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	788	9.572737411	34.11439971	TUN	Tunisia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	788	9.572737411	34.11439971	TUN	Tunisia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	788	9.572737411	34.11439971	TUN	Tunisia	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	788	9.572737411	34.11439971	TUN	Tunisia	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	788	9.572737411	34.11439971	TUN	Tunisia	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	35.42890329	38.9899684	TUR	Turkey	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	35.42890329	38.9899684	TUR	Turkey	1	PERCENT	Percentage	2009	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	35.42890329	38.9899684	TUR	Turkey	1	PERCENT	Percentage	2010	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	35.42890329	38.9899684	TUR	Turkey	1	PERCENT	Percentage	2011	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	35.42890329	38.9899684	TUR	Turkey	1	PERCENT	Percentage	2012	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	35.42890329	38.9899684	TUR	Turkey	1	PERCENT	Percentage	2013	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	35.42890329	38.9899684	TUR	Turkey	1	PERCENT	Percentage	2014	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	35.42890329	38.9899684	TUR	Turkey	1	PERCENT	Percentage	2015	97	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	35.42890329	38.9899684	TUR	Turkey	1	PERCENT	Percentage	2016	98	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	795	58.9787665	40.0912346	TKM	Turkmenistan	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	795	58.9787665	40.0912346	TKM	Turkmenistan	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	795	58.9787665	40.0912346	TKM	Turkmenistan	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	795	58.9787665	40.0912346	TKM	Turkmenistan	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	795	58.9787665	40.0912346	TKM	Turkmenistan	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	795	58.9787665	40.0912346	TKM	Turkmenistan	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	795	58.9787665	40.0912346	TKM	Turkmenistan	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	795	58.9787665	40.0912346	TKM	Turkmenistan	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	795	58.9787665	40.0912346	TKM	Turkmenistan	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	796	-71.745121	21.80780585	TCA	Turks and Caicos Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	796	-71.745121	21.80780585	TCA	Turks and Caicos Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	796	-71.745121	21.80780585	TCA	Turks and Caicos Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	796	-71.745121	21.80780585	TCA	Turks and Caicos Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	796	-71.745121	21.80780585	TCA	Turks and Caicos Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	796	-71.745121	21.80780585	TCA	Turks and Caicos Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	796	-71.745121	21.80780585	TCA	Turks and Caicos Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	796	-71.745121	21.80780585	TCA	Turks and Caicos Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	796	-71.745121	21.80780585	TCA	Turks and Caicos Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	798	178.6679611	-7.460048071	TUV	Tuvalu	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	798	178.6679611	-7.460048071	TUV	Tuvalu	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	798	178.6679611	-7.460048071	TUV	Tuvalu	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	798	178.6679611	-7.460048071	TUV	Tuvalu	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	798	178.6679611	-7.460048071	TUV	Tuvalu	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	798	178.6679611	-7.460048071	TUV	Tuvalu	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	798	178.6679611	-7.460048071	TUV	Tuvalu	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	798	178.6679611	-7.460048071	TUV	Tuvalu	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	798	178.6679611	-7.460048071	TUV	Tuvalu	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	32.39100438	1.279557331	UGA	Uganda	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	32.39100438	1.279557331	UGA	Uganda	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	32.39100438	1.279557331	UGA	Uganda	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	32.39100438	1.279557331	UGA	Uganda	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	32.39100438	1.279557331	UGA	Uganda	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	32.39100438	1.279557331	UGA	Uganda	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	32.39100438	1.279557331	UGA	Uganda	1	PERCENT	Percentage	2014	50	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	32.39100438	1.279557331	UGA	Uganda	1	PERCENT	Percentage	2015	66	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	32.39100438	1.279557331	UGA	Uganda	1	PERCENT	Percentage	2016	78	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	804	31.40270802	49.00735945	UKR	Ukraine	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	804	31.40270802	49.00735945	UKR	Ukraine	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	804	31.40270802	49.00735945	UKR	Ukraine	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	804	31.40270802	49.00735945	UKR	Ukraine	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	804	31.40270802	49.00735945	UKR	Ukraine	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	804	31.40270802	49.00735945	UKR	Ukraine	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	804	31.40270802	49.00735945	UKR	Ukraine	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	804	31.40270802	49.00735945	UKR	Ukraine	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	804	31.40270802	49.00735945	UKR	Ukraine	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	807	21.7007909	41.60048068	MKD	Macedonia, Republic of	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	807	21.7007909	41.60048068	MKD	Macedonia, Republic of	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	807	21.7007909	41.60048068	MKD	Macedonia, Republic of	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	807	21.7007909	41.60048068	MKD	Macedonia, Republic of	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	807	21.7007909	41.60048068	MKD	Macedonia, Republic of	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	807	21.7007909	41.60048068	MKD	Macedonia, Republic of	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	807	21.7007909	41.60048068	MKD	Macedonia, Republic of	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	807	21.7007909	41.60048068	MKD	Macedonia, Republic of	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	807	21.7007909	41.60048068	MKD	Macedonia, Republic of	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	818	29.77468534	26.57438204	EGY	Egypt	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	818	29.77468534	26.57438204	EGY	Egypt	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	818	29.77468534	26.57438204	EGY	Egypt	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	818	29.77468534	26.57438204	EGY	Egypt	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	818	29.77468534	26.57438204	EGY	Egypt	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	818	29.77468534	26.57438204	EGY	Egypt	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	818	29.77468534	26.57438204	EGY	Egypt	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	818	29.77468534	26.57438204	EGY	Egypt	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	818	29.77468534	26.57438204	EGY	Egypt	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	-2.23830539	53.27691757	GBR	United Kingdom	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	-2.23830539	53.27691757	GBR	United Kingdom	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	-2.23830539	53.27691757	GBR	United Kingdom	1	PERCENT	Percentage	2010	89	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	-2.23830539	53.27691757	GBR	United Kingdom	1	PERCENT	Percentage	2011	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	-2.23830539	53.27691757	GBR	United Kingdom	1	PERCENT	Percentage	2012	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	-2.23830539	53.27691757	GBR	United Kingdom	1	PERCENT	Percentage	2013	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	-2.23830539	53.27691757	GBR	United Kingdom	1	PERCENT	Percentage	2014	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	-2.23830539	53.27691757	GBR	United Kingdom	1	PERCENT	Percentage	2015	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	-2.23830539	53.27691757	GBR	United Kingdom	1	PERCENT	Percentage	2016	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	831	-2.200712402	49.71561166	GGY	Guernsey	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	831	-2.200712402	49.71561166	GGY	Guernsey	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	831	-2.200712402	49.71561166	GGY	Guernsey	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	831	-2.200712402	49.71561166	GGY	Guernsey	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	831	-2.200712402	49.71561166	GGY	Guernsey	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	831	-2.200712402	49.71561166	GGY	Guernsey	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	831	-2.200712402	49.71561166	GGY	Guernsey	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	831	-2.200712402	49.71561166	GGY	Guernsey	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	831	-2.200712402	49.71561166	GGY	Guernsey	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	832	-2.136773508	49.22353354	JEY	Jersey	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	832	-2.136773508	49.22353354	JEY	Jersey	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	832	-2.136773508	49.22353354	JEY	Jersey	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	832	-2.136773508	49.22353354	JEY	Jersey	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	832	-2.136773508	49.22353354	JEY	Jersey	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	832	-2.136773508	49.22353354	JEY	Jersey	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	832	-2.136773508	49.22353354	JEY	Jersey	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	832	-2.136773508	49.22353354	JEY	Jersey	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	832	-2.136773508	49.22353354	JEY	Jersey	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	833	-4.538190305	54.22880901	IMN	Isle of Man	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	833	-4.538190305	54.22880901	IMN	Isle of Man	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	833	-4.538190305	54.22880901	IMN	Isle of Man	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	833	-4.538190305	54.22880901	IMN	Isle of Man	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	833	-4.538190305	54.22880901	IMN	Isle of Man	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	833	-4.538190305	54.22880901	IMN	Isle of Man	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	833	-4.538190305	54.22880901	IMN	Isle of Man	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	833	-4.538190305	54.22880901	IMN	Isle of Man	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	833	-4.538190305	54.22880901	IMN	Isle of Man	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	34.80521182	-6.265332606	TZA	Tanzania, United Republic of	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	34.80521182	-6.265332606	TZA	Tanzania, United Republic of	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	34.80521182	-6.265332606	TZA	Tanzania, United Republic of	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	34.80521182	-6.265332606	TZA	Tanzania, United Republic of	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	34.80521182	-6.265332606	TZA	Tanzania, United Republic of	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	34.80521182	-6.265332606	TZA	Tanzania, United Republic of	1	PERCENT	Percentage	2013	80	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	34.80521182	-6.265332606	TZA	Tanzania, United Republic of	1	PERCENT	Percentage	2014	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	34.80521182	-6.265332606	TZA	Tanzania, United Republic of	1	PERCENT	Percentage	2015	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	34.80521182	-6.265332606	TZA	Tanzania, United Republic of	1	PERCENT	Percentage	2016	96	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	-99.13830311	39.5277871	USA	United States of America	1	PERCENT	Percentage	2008	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	-99.13830311	39.5277871	USA	United States of America	1	PERCENT	Percentage	2009	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	-99.13830311	39.5277871	USA	United States of America	1	PERCENT	Percentage	2010	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	-99.13830311	39.5277871	USA	United States of America	1	PERCENT	Percentage	2011	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	-99.13830311	39.5277871	USA	United States of America	1	PERCENT	Percentage	2012	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	-99.13830311	39.5277871	USA	United States of America	1	PERCENT	Percentage	2013	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	-99.13830311	39.5277871	USA	United States of America	1	PERCENT	Percentage	2014	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	-99.13830311	39.5277871	USA	United States of America	1	PERCENT	Percentage	2015	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	-99.13830311	39.5277871	USA	United States of America	1	PERCENT	Percentage	2016	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	850	-64.76960113	17.73297693	VIR	United States Virgin Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	850	-64.76960113	17.73297693	VIR	United States Virgin Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	850	-64.76960113	17.73297693	VIR	United States Virgin Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	850	-64.76960113	17.73297693	VIR	United States Virgin Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	850	-64.76960113	17.73297693	VIR	United States Virgin Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	850	-64.76960113	17.73297693	VIR	United States Virgin Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	850	-64.76960113	17.73297693	VIR	United States Virgin Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	850	-64.76960113	17.73297693	VIR	United States Virgin Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	850	-64.76960113	17.73297693	VIR	United States Virgin Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	-1.742843829	12.27491081	BFA	Burkina Faso	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	-1.742843829	12.27491081	BFA	Burkina Faso	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	-1.742843829	12.27491081	BFA	Burkina Faso	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	-1.742843829	12.27491081	BFA	Burkina Faso	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	-1.742843829	12.27491081	BFA	Burkina Faso	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	-1.742843829	12.27491081	BFA	Burkina Faso	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	-1.742843829	12.27491081	BFA	Burkina Faso	1	PERCENT	Percentage	2014	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	-1.742843829	12.27491081	BFA	Burkina Faso	1	PERCENT	Percentage	2015	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	-1.742843829	12.27491081	BFA	Burkina Faso	1	PERCENT	Percentage	2016	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	-56.01387025	-32.8002838	URY	Uruguay	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	-56.01387025	-32.8002838	URY	Uruguay	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	-56.01387025	-32.8002838	URY	Uruguay	1	PERCENT	Percentage	2010	91	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	-56.01387025	-32.8002838	URY	Uruguay	1	PERCENT	Percentage	2011	92	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	-56.01387025	-32.8002838	URY	Uruguay	1	PERCENT	Percentage	2012	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	-56.01387025	-32.8002838	URY	Uruguay	1	PERCENT	Percentage	2013	93	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	-56.01387025	-32.8002838	URY	Uruguay	1	PERCENT	Percentage	2014	95	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	-56.01387025	-32.8002838	URY	Uruguay	1	PERCENT	Percentage	2015	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	-56.01387025	-32.8002838	URY	Uruguay	1	PERCENT	Percentage	2016	94	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	860	63.11944558	41.77560518	UZB	Uzbekistan	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	860	63.11944558	41.77560518	UZB	Uzbekistan	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	860	63.11944558	41.77560518	UZB	Uzbekistan	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	860	63.11944558	41.77560518	UZB	Uzbekistan	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	860	63.11944558	41.77560518	UZB	Uzbekistan	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	860	63.11944558	41.77560518	UZB	Uzbekistan	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	860	63.11944558	41.77560518	UZB	Uzbekistan	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	860	63.11944558	41.77560518	UZB	Uzbekistan	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	860	63.11944558	41.77560518	UZB	Uzbekistan	1	PERCENT	Percentage	2016	99	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	-66.15642084	7.121324748	VEN	Venezuela (Bolivarian Republic)	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	-66.15642084	7.121324748	VEN	Venezuela (Bolivarian Republic)	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	-66.15642084	7.121324748	VEN	Venezuela (Bolivarian Republic)	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	-66.15642084	7.121324748	VEN	Venezuela (Bolivarian Republic)	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	-66.15642084	7.121324748	VEN	Venezuela (Bolivarian Republic)	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	-66.15642084	7.121324748	VEN	Venezuela (Bolivarian Republic)	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	-66.15642084	7.121324748	VEN	Venezuela (Bolivarian Republic)	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	-66.15642084	7.121324748	VEN	Venezuela (Bolivarian Republic)	1	PERCENT	Percentage	2015	24	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	-66.15642084	7.121324748	VEN	Venezuela (Bolivarian Republic)	1	PERCENT	Percentage	2016	7	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	876	-176.2034788	-13.28471201	WLF	Wallis and Futuna Islands	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	876	-176.2034788	-13.28471201	WLF	Wallis and Futuna Islands	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	876	-176.2034788	-13.28471201	WLF	Wallis and Futuna Islands	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	876	-176.2034788	-13.28471201	WLF	Wallis and Futuna Islands	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	876	-176.2034788	-13.28471201	WLF	Wallis and Futuna Islands	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	876	-176.2034788	-13.28471201	WLF	Wallis and Futuna Islands	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	876	-176.2034788	-13.28471201	WLF	Wallis and Futuna Islands	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	876	-176.2034788	-13.28471201	WLF	Wallis and Futuna Islands	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	876	-176.2034788	-13.28471201	WLF	Wallis and Futuna Islands	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	882	-172.4430749	-13.61541469	WSM	Samoa	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	882	-172.4430749	-13.61541469	WSM	Samoa	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	882	-172.4430749	-13.61541469	WSM	Samoa	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	882	-172.4430749	-13.61541469	WSM	Samoa	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	882	-172.4430749	-13.61541469	WSM	Samoa	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	882	-172.4430749	-13.61541469	WSM	Samoa	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	882	-172.4430749	-13.61541469	WSM	Samoa	1	PERCENT	Percentage	2014					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	882	-172.4430749	-13.61541469	WSM	Samoa	1	PERCENT	Percentage	2015					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	882	-172.4430749	-13.61541469	WSM	Samoa	1	PERCENT	Percentage	2016					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	45.22389143	15.22242099	YEM	Yemen	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	45.22389143	15.22242099	YEM	Yemen	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	45.22389143	15.22242099	YEM	Yemen	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	45.22389143	15.22242099	YEM	Yemen	1	PERCENT	Percentage	2011	41	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	45.22389143	15.22242099	YEM	Yemen	1	PERCENT	Percentage	2012	67	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	45.22389143	15.22242099	YEM	Yemen	1	PERCENT	Percentage	2013	73	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	45.22389143	15.22242099	YEM	Yemen	1	PERCENT	Percentage	2014	73	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	45.22389143	15.22242099	YEM	Yemen	1	PERCENT	Percentage	2015	69	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	45.22389143	15.22242099	YEM	Yemen	1	PERCENT	Percentage	2016	71	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	27.850329	-14.59701056	ZMB	Zambia	1	PERCENT	Percentage	2008					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	27.850329	-14.59701056	ZMB	Zambia	1	PERCENT	Percentage	2009					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	27.850329	-14.59701056	ZMB	Zambia	1	PERCENT	Percentage	2010					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	27.850329	-14.59701056	ZMB	Zambia	1	PERCENT	Percentage	2011					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	27.850329	-14.59701056	ZMB	Zambia	1	PERCENT	Percentage	2012					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	27.850329	-14.59701056	ZMB	Zambia	1	PERCENT	Percentage	2013					
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	27.850329	-14.59701056	ZMB	Zambia	1	PERCENT	Percentage	2014	77	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	27.850329	-14.59701056	ZMB	Zambia	1	PERCENT	Percentage	2015	81	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
2018.Q2.G.01	SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	27.850329	-14.59701056	ZMB	Zambia	1	PERCENT	Percentage	2016	90	Float		WHO/UNICEF coverage estimates 2016 revision, July 2017	E
